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Abstract 
A limitless proliferative potential is one of the hallmarks of tumour 
cells and can be achieved through the activation of telomere 
maintenance mechanisms (TMM), which rely on telomerase reactivation 
(TA) or, alternatively, on recombination-based processes known as 
alternative lengthening of telomeres (ALT). Since a substantial fraction 
of tumours of mesenchymal origin utilizes ALT mechanisms, they 
represent an interesting model to study the molecular pathways involved 
in the activation of TMM.  
With the present work, we extended our knowledge about the 
prevalence and the prognostic significance of the two known TMMs in 
different soft-tissue sarcoma histotypes (Malignant peripheral nerve 
sheath tumors –MPNST-, leiomyosarcoma, liposarcoma) and mixed 
origin tumours (Wilms’ tumour), showing the relatively low frequency of 
telomerase activity in soft tissue sarcomas if compared to tumors of 
epithelial origin, and the important role of ALT in these malignancies. 
Controversial results have been obtained about the clinical relevance of 
TMMs, whose prognostic role seems to be dependent on tumor 
histotypes. Specifically, ALT is a strong determinant of an unfavorable 
outcome in liposarcoma and leiomyosarcoma patients, whereas it failed 
to significantly affect the outcome of patients with MPNST (for whom TA 
proved to be an important predictor of poor survival).  
This scenario could be due, at least in part, to the lack of standardized 
methods to properly classify tumours with respect to their TMM status; in 
this context, we comparatively analysed the prognostic relevance of ALT 
in a series of liposarcoma as a function of the characteristic used to 
classify the tumour, with the final aim to identify the most suitable ALT 
marker. 
Moreover, we also proposed to identify microRNAs expressed as a 
function of the different TMM operating in the tumour, which could be 
either involved in the regulation of such mechanisms or represent 
surrogate markers of TA-positive or ALT-positive phenotypes.  
The knowledge of the specific factors/pathways by which the two known 
TMMs are differentially regulated in distinct tumour histotypes of 
mesenchymal origin might be important for a better understanding of the 
pathogenesis of these malignancies and for the identification of new 
therapeutic targets. 
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State of the Art
The process of carcinogenesis involves a number of changes in cellular 
phenotype, which are largely based on acquired genetic alterations in 
cells that are not terminally differentiated. The ability of cancer cells to 
grow and their failure to respond to the usual controls on such 
proliferation are obvious features, but they can also evade cell death 
and most have no limits on their ability to replicate beyond the limits 
imposed by telomere length in normal cells.  
By 2000, it was widely accepted that cancer cells require unlimited 
replicative potential in order to generate macroscopic tumours. This 
capability stands in marked contrast to the behaviour of the cells in most 
normal cell lineages in the body, which are able to pass through only a 
limited number of successive cell growth-and-division cycles. This 
limitation has been associated with two distinct barriers to proliferation: 
senescence, which is an irreversible nonproliferative state, and crisis, 
which leads to cell death. Accordingly, when cells are propagated in 
culture, repeated cycles of cell division lead first to senescence and then 
to crisis, a phase in which the majority of cells in the population die. 
Rarely, some cells can emerge from a population in crisis and exhibit 
unlimited replicative potential (immortalization). Multiple lines of 
evidence indicate that telomeres protecting the ends of chromosomes 
are centrally involved in the capability for unlimited proliferation (Blasco, 
2005; Shay and Wright, 2000). 
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The telomere 
Telomeres are essential components of linear chromosomes, but their 
existence was postulated several years before the discover of the DNA 
double helix. In the late 1930s, Hermann Muller and Barbara McClintock 
independently noted that the ends of chromosomes (termed “telomeres” 
or “natural ends”) were not as sticky as broken chromosomal ends. 
Decades later, after the discovery of the structure of DNA, Alexey 
Olovnikov implicated telomeres in the “Hayflick limit” of cellular 
duplication; further, he realized that in DNA semi-conservative 
replication, the replica would always be shorter than the template, 
eventually producing extremely short chromosomes and senescent 
cells; this theory hypothesized that telomeres would buffer genetic loss 
with each mitotic divisions and that telomere shortening could explain 
many aging-related disorders. Telomeres are DNA-protein structures 
that distinguish natural chromosome ends from double strand breaks 
(DSBs). Because telomeres protect chromosome ends from processing 
events that result in degradation and/or end-to-end fusions, they are 
essential for chromosome integrity.  
Telomeric DNA consists of a tandem array of short repeated sequences, 
in which the strand running 5’–3’ from the centromere towards the 
chromosome end is usually guanine-rich, specifically, in human species 
the tandem repeated sequence is TTAGGG. The amount of duplex 
telomeric DNA per chromosome end varies enormously among different 
species and in mammals reaches more than 10kb. Extension of the 
guanine-rich strand forms a conserved feature of telomere structure, so 
called G-tail, of 30 single stranded overhang which plays a crucial role in 
telomere function (Cech T.R., 2004, Chan S.W.-L. 2003,  deLange T. 
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2005, Dionne I. 1996, Wellinger R.J. 1997).  
As part of their end-protection function, telomeric DNA is constitutively 
bound by a core complex of proteins called shelterin. Shelterin 
components include both duplex (TRF proteins in mammals, Rap1 in S. 
cerevisiae, Taz1 in S. pombe) and single strand (Pot1 in mammals and 
S. pombe, Cdc13 in S. cerevisiae) binding proteins as well as proteins 
that associate via protein–protein interactions (deLange T. 2005,
Rhodes  D. 2002, Palm, W., 2009, Vega, L. 2003). 
Figure 1. telomere structure. Telomeric DNA and telomere-binding proteins. 
The overall composition of the shelterin complex varies between species 
in respect to protein content and higher order structure, but the general 
design is conserved (Linger B.R., 2009). The role of the shelterin 
complex in telomere function and regulation includes distinguishing 
natural ends from DNA breaks and recruiting telomerase to DNA ends 
(Palm, W., 2009). In addition to the shelterin complex, higher-order DNA 
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structures are thought to contribute to telomere functions. A well 
documented example of such structures are T-loops forming when the 
single stranded telomeric G- overhang invades the double stranded 
telomeric region of the same chromosome (Makarov V.L., 1997). By 
sequestering chromosome ends, T-loops are proposed to protect 
telomeres against checkpoint recognition, DNA repair, and telomerase-
mediated extension (Griffith J.D., 1999, Poulet, 2009, van Steensel B., 
1998). Since T- loops are structurally similar to Holliday junctions, they 
may also be important for telomere recombination (Dunham M.A., 2000, 
Stansel R.M., 2002). It is not yet known if T-loops exist at each telomere, 
how they are regulated in the cell cycle, or how they are displaced to 
allow both semi-conservative and telomerase-mediated telomere 
replication. G-quadruplex structures are another secondary DNA 
structure that can affect telomere function. G-quadruplexes involve the 
association of four guanines into a cyclic Hoogsteen hydrogen bonding 
arrangement in which each guanine shares a hydrogen bond with its 
neighbor (N1–O6 and N2–N7). The G-rich single stranded telomeric 
overhang can form intra- and inter- molecular G-quadruplex structures in 
vitro. 
Telomere maintenance mechanisms 
Since linear chromosomes shorten with every round of DNA replication 
and cell division, leading cells to replicative senescence or apoptosis 
(Gilson E, 2007), telomere maintenance is crucial for cells to escape a 
crisis and to become immortalized. For this reason, the activation of a 
telomere maintenance mechanism (TMM) is essential for the 
transformation of most human cancer cells. In a high percentage of 
human tumours (more than 85%), proliferation-dependent telomere 
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shortening is counterbalanced by the synthesis of telomeric sequences 
by telomerase (Folini M, 2009). However, there are human tumours, 
about 15%, that lack telomerase and maintain telomere length by a 
pathway known as the alternative lengthening of telomeres (ALT) 
mechanism (Cesare AJ, 2010). 

Figure 2: Primary cells divide exponentially, and telomeres shorten until they 
reach a critical length and irreversible cell-cycle arrest then occurs 
(senescence). Activation of TMM allows cells to divide indefinitely until end 
protection is completely lost, resulting in telomeric crisis, cell death and 
massive genomic instability. Activation of telomerase or other TMMs after the 
accumulation of mutations allows clones that carry multiple mutations to 
escape cell death (that is, to become immortal). Such cells are predisposed to 
oncogenic transformation. PD, population doublings
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Telomerase 
The minimal telomerase enzyme consists of a protein subunit (TERT) 
and an integral RNA component (TR), which contains the template used 
by TERT to add multiple identical repeats of DNA to the ends of 
chromosomes, a process known as repeat addition processivity 
(Blackburn EH, 2000, Shippen-Lentz D. 1990, Miller MC 2000, Lai CK 
2002, Lamond AI 1989). The initiation of telomere replication requires 
that the enzyme telomerase is recruited to the telomeres, usually by a 
single-stranded telomere binding protein such as, in humans, the 
components of the shelterin complex, TPIP1 and POT1 (Xin H, 2007). 
Telomerase loading to the telomeres leads to partial pairing of the 
template RNA with the DNA overhang and positioning of the 3-end of 
the telomeric DNA at the active site of the enzyme for catalysis. 
Following replication of one telomeric repeat, the RNA–DNA hybrid 
transiently dissociates to allow for pairing of the DNA overhang with the 
distal region of the RNA-templating region and initiation of replication of 
another telomeric repeat (Lee MS 1993) (Figure 3). 
Although TR and TERT are sufficient to obtain telomerase activity in 
vitro, additional protein components such as dyskerin and telomerase 
Cajal body protein 1 are required for the correct assembly and trafficking 
of the enzyme in human cells (Folini M, 2009, Mitchell M, 2010, 
Venteicher AS, 2009). In addition to its role in maintaining chromosome 
ends through the regulation of telomere length, telomerase has been 
recently implicated in providing growth-promoting properties to tumour 
cells, independently of its catalytic activity (Bollmann FM., 2008). 
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Figure 3: telomere extension by telomerase. 
There are currently a number of methods used to detect telomerase 
activity. The telomeric repeat amplification protocol assay (TRAP), a 
method based on a polymerase chain reaction (PCR) (Figure 4), has 
become the standard method for studying the diagnostic relevance of 
the enzyme (Kim NW, 1994) (for further details see Part II, Published 
Papers, materials and methods). Telomerase activity has also been 
investigated qualitatively and quantitatively using several modified TRAP 
protocols. Other methods focused on the detection of the telomerase 
components, hTERT and hTR, by reverse transcriptase PCR (RT-PCR) 
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methods. In particular, real-time PCR methods in more recent years 
allowed the quantitative determination of telomerase subunits.  
Figure 4 schematic representation of TRAP assay 
During the process of carcinogenesis, telomerase is activated at 
different stages. In some instances, telomerase can be activated 
gradually throughout the progression of the cancer, whereas in other 
cases, this enzyme might already be expressed at the in situ or 
precancerous stage. These differences might affect the clinical utility of 
telomerase as a diagnostic marker or prognostic index. Early studies of 
telomerase activity in cancerous tissue were marked by the use of 
different approaches; different objectives were stipulated and several 
methods, both qualitative and quantitative, were used. Initially, most 
Telomere maintenance mechanisms in mesenchymal tumours_______________
16 
studies aimed at analyzing telomerase activity in cancerous lesion and 
the surrounding macroscopically healthy tissue. Later, the main 
objective of these studies was to verify whether telomerase activity could 
offer a reliable and non-invasive diagnostic or prognostic tool.  
One problem for the TRAP assay is that it is a solution-phase technique, 
thus, information about the cell type that expresses the telomerase is 
lost. Cancer cells, as well as some cells from healthy tissue and benign 
lesions (including germ cells, lymphocytes, stem or its progenitor cells, 
and certain epithelial cells) exhibit telomerase activity; therefore, it is not 
possible to know whether telomerase activity is coming from the tumour 
cells in the sample. To overcome this limitation, an in situ TRAP assay, 
which uses fluorescent dyes and microscopy to visualize telomerase 
activity in the nuclei of cells of interest, is needed to determine whether 
telomerase expression is derived from normal telomerase-positive cells 
or from malignant cells. Another solution is to use quantitative TRAP or 
real-time PCR methods to define threshold values that can help 
distinguish cancer from normal tissue. 
Telomerase is activated in about 85% of human cancers and its 
expression is not usually detectable in somatic cells; therefore, its 
detection holds promise as a diagnostic tool for many types of tumour. In 
addition, telomerase is also activated in some premalignant tissue; thus, 
it is reasonable for physicians to expect that testing for telomerase 
activity is a useful method for the screening of high-risk patients. Hence, 
it is crucial to determine which cancers possess early robust telomerase 
activity and which manifest little to no telomerase activity, even in the 
most advanced stages of malignancy. Expression of the TR subunit has 
been found in all cells, irrespectively from the presence of telomerase 
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expression and activity, although it could be often amplified in cancer 
cells. By counterpart, TERT expression correlates with telomerase 
activity because its presence is essential for enzymatic activity. Thus, 
detection of the TERT mRNA is considered to be a more reliable marker 
of the presence of cancer cells in clinical samples, although its presence 
is necessary but not sufficient to obtain an active form of the enzyme 
(Villa R, 2001; Villa R, 2008; Zaffaroni N, 2005). 
Due to its selective reactivation in most human tumours, the possibility 
to interfere with telomerase expression and functions has been 
considered a useful strategy for the development of effective anticancer 
therapies since its discovery (Folini M, 2007; Shay JW, 2006). 
Data obtained from preclinical studies concerning the effects of 
telomerase inhibition have provided compelling arguments to indicate 
that the enzyme is a well-validated cancer target (Folini M, 2011). Data 
obtained from preclinical studies on the effects of telomerase inhibition 
have provided compelling arguments to indicate that the enzyme is a 
well-validated cancer target and have led the enzyme’s inhibitor 
GRN163L to enter the first clinical trials — as a single agent or in 
combination with conventional anticancer drugs — for different 
malignancies (Harley C.B., 2008) (For more details see Part II, 
published manuscript: “Telomeres as targets for anticancer therapies”). 
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Alternative lengthening of telomeres 
Some cell lines and tumour do not use telomerase to maintain 
telomeres, but a telomerase-independent mechanism, referred to as 
Alternative Lengthening of Telomeres (ALT) (Bryan TM, 1995). Although 
the definition of ALT encompasses any non-telomerase TMM (Bryan TM 
1997), so far there is no clear evidence that there is more than one ALT 
mechanism in human cells. In contrast to RNA-templated DNA synthesis 
by telomerase, synthesis of new telomeric DNA by ALT involves the use 
of a DNA template (Dunham MA, 2000).  It has been suggested that the 
homologous-recombination machinery is responsible for the 
amplification of the telomeric sequences in ALT cells, because a 
selection marker introduced into telomeres of ALT and non-ALT cells 
spreads throughout telomeres only in ALT cells (Dunham, M. A, 2000) 
ALT cells show an increased rate of sister chromatid exchange (Bailey 
SM, 2004; Bechter OE, 2004) suggesting that the homologous-
recombination pathway is involved. 

Figure 5 Telomere dynamic in ALT cells. 
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The maintenance of telomere length in a telomerase-independent way 
was first described in yeast, where genetic analyses demonstrated it 
was dependent on homologous recombination (HR) (Lundblad V, 1993). 
The existence of an ALT mechanism in mammalian cells was deduced 
from the observation that telomere lengths were maintained for 
hundreds of population doublings (PD) in telomerase-negative 
immortalized human cell lines (Bryan TM 1995, Rogan EM, 1995).  
With few exceptions, human ALT positive cells show a characteristic 
pattern of telomere length heterogeneity, with telomeres ranging from 
very short to greater than 50 kb long and the presence of ALT-
associated promyelocitic leukaemia (PML) nuclear bodies (APBs), 
containing telomeric DNA (TTAGGG)n and telomere-specific binding 
proteins (Yeager TR, 1999). 
APBs are a subset of PML bodies that are present only in ALT cells, and 
are not found in mortal cells or telomerase-positive cells (Yeager TR, 
1999). Constitutive components of APBs are telomeric DNA, PML 
protein (specifically, PML3 isoform (Yu, J., 2010) and Sp100 protein, in 
addition to telomere-associated proteins such as the Shelterin Complex. 
Telomeric chromatin needs to be SUMOylated by the SMC 5/6 complex 
(Potts PR, 2007) and a functional MRN complex needs to be involved in 
DNA recombination (Jiang WQ, 2009). APBs also contain other proteins 
involved in DNA replication, recombination and repair including RAD51, 
RAD52, RPA (Yeager TR, 1999), WRN (Johnson FB, 2001), BRCA1, 
MRE11, RAD50, NBS1 (Zhu XD, 2000; Wu G, 2000). 
Although definitive evidence is still lacking, it has long been thought that 
APBs might have a pivotal role in the ALT mechanism process (), and 
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consistent with this suggestion, inhibition of ALT in some somatic cell 
hybrids formed by fusion of ALT and telomerase-positive cell lines 
resulted in a substantial decrease in APBs (Perrem K, 2001). APBs can 
be also found in nearly 5% of exponentially dividing “normal” ALT cells, 
suggesting that APBs can be actually functionally heterogeneous, with 
only a subset being directly involved in ALT mechanisms.  
Figure  6: A hypothetical model for APB formation in ALT cells. Telomeric DNA 
binds to the MRN complex via RAP1, and then translocates to PML bodies to 
form APBs. 
Another specific feature of ALT mechanisms is C-circles (self-priming 
circular telomeric DNA), which may represent molecular intermediates of 
the ALT mechanisms and whose specificity for assessing ALT activity in 
biological samples has recently been demonstrated (Henson J, 2010). 
Showing that a cell line is able to maintain the length of its telomeres in 
the absence of telomerase activity for several population doublings is 
still the only definitive test for the presence of ALT activity, but of course 
is not a suitable assay to detect ALT activity in human tumours because 
it would take a long time and several metacrhounous lesions should be 
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available. Furthermore, this assay is not suitable for detecting ALT when 
both ALT and telomerase may be present.  
Without the availability of a specific assay for ALT activity, its presence 
in tumours has been deduced from peculiar phenotypic features of ALT-
positive cell lines which are currently used as surrogate markers of ALT. 
As already described above, the first hallmark found in immortalized 
human ALT-positive cell was a characteristic pattern of telomere lengths 
that can be observed by terminal restriction fragment (TRF) Southern 
blot analysis (Figure 7). The modal length in ALT cells is approximately 
twice that in comparable telomerase-positive or normal cells (Bryan TM, 
1995, Gollahon LS, 1998).  
Figure 7: Representative examples of tumour specimens defined as ALT-
positive (left) or ALT-negative (right) on the basis of telomere length. 
The telomere length heterogeneity can also be visualized in metaphase 
spreads by telomere fluorescence in situ hybridization (FISH) (Perrem K, 
2001). Telomere lengths in ALT cells are not normally distributed, in 
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contrast to telomerase-positive cells, most of which regulate their 
telomere lengths about a mean of 5–10kb (Henson JD, 2002, Jeyapalan 
JN, 2008). 
The long heterogeneous telomere length pattern remains the best-
established marker for ALT in human cells, including tumours archived 
under conditions where it is possible to extract high-quality genomic 
DNA (Bryan TM, 1997; Henson JD, 2005). In tumour specimens the 
distinction between ALT+ and ALT- is sometimes less obvious due to 
tumour heterogeneity and to the admixture of non-tumour cells in the 
specimen (Henson JD, 2005; Venturini L, 2010). For these reasons, 
tumour length heterogeneity needs to be interpreted cautiously by an 
expert operator. 
Also the assessment of APB presence by a combined technique of 
immunofluorescence for PML protein and telomere FISH (Yeager TR, 
1999) has become a well-established test for ALT (Figure 8).  APB 
assay has been especially useful for determining the ALT status of 
tumours as it can be used on paraffin embedded specimens (Venturini 
L, 2008), and it is not affected by intra-tumoural heterogeneity in TMM 
because it assesses individual cells (Henson JD, 2005, Venturini L., 
2010). 
The lack of standardized methods for ALT determination has major 
implications for the classification of ALT+ tumours. In this context, in 
liposarcoma, the instability at the minisatellite MS32 — usually 
associated with ALT activation — and the presence of complex telomere 
mutations have been reported to aid the identification of tumours that 
have recombination-like activity at telomeres in the absence of APBs 
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(Jeyapalan J.N., 2008), suggesting that the incidence of ALT may be 
underestimated using the available methods. 
Figure 8: APB assay performed on a tumour frozen section by PML 
immunofluorescence (green stain) and telomere FISH (red stain). Co 
localization of the signals determines the presence of an APB.  
As these TMMs are either undetectable or have low levels of activity in 
normal somatic cells (R.R. Reddel, 2000, Shay JW 1997), they provide 
important targets for detection and treatment of cancer cells. ALT is 
being found in an increasing number of cancer types, including some 
that have a very poor prognosis with currently available treatments. 
However, inhibitors that specifically target the ALT pathway have not yet 
been described, probably as a consequence of the fragmentary 
information about the molecular events driving such a mechanism. 
Based on results of a recent survey aimed to comparatively evaluate the 
expression levels of telomere-related proteins in normal and tumour 
tissues, none of these proteins stands out as a novel cancer-related 
target (Cookson JC, 2009). 
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Tumours of mesenchymal origin. 
Tumours of mesenchymal origin cover a broad range of uncommon but 
diverse malignancies such as sarcomas, that arise from bone, cartilage 
or connective tissues (e.g. muscle, fat, peripheral nerves and fibrous or 
related tissues). Increasingly, human mesenchymal malignancies are 
being classified by the abnormalities that drive their pathogenesis. 
Although many of these aberrations are highly prevalent within particular 
sarcoma subtypes, very few of them are currently targeted 
therapeutically. Indeed, most subtypes of sarcoma and other 
mesenchymal neoplasms are still treated with traditional therapeutic 
modalities, and in many cases sarcomas are resistant to adjuvant 
therapies thus given the need for new therapies in such malignancies. In 
particular, in our studies we focused on: 
Liposarcoma: the largest single group of soft-tissue tumours, accounting 
for 20% of all mesenchymal malignancies. This group is composed of 
three categories: well-differentiated and dedifferentiated liposarcoma, 
myxoid and round cell liposarcoma, pleomorphic liposarcoma. While 
clustered together, these histological subtypes are widely diverse in their 
clinical, pathological, and molecular characteristics. In general, surgery 
still remains the mainstay of therapy and the only approach offering the 
potential of cure Risk of recurrence is high for patients with 
dedifferentiated histology or retroperitoneal location (Hoffman A, 2010). 
Leiomyosarcoma: a malignant neoplasm arising from smooth muscle 
cells. It’s a relatively rare form of cancer, comprising 5-10% of soft tissue 
sarcomas. These malignancies are generally not very responsive to 
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chemotherapy or radiation therapy and the best patients’ outcome 
occurs when the tumour can be surgically removed with wide margins. 
Uterine leiomyosarcomas is a very common type arising from the 
smooth muscle layer of the uterus.(van Vliet, 2009)  
Malignant peripheral nerve sheath tumours (MPNST): a group of rare 
soft tissue neoplasms accounting for 3-10% of all soft tissue sarcomas 
that most commonly involve major nerve trunks. MPNSTs are highly 
aggressive malignancies, complete surgical excision is the primary 
curative modality. Approximately half of MPNSTs occur in the setting of 
neurofibromatosis type 1 (NF1), a hereditary tumour syndrome, while 
the remainder of MPNSTs develop sporadically (Anghileri M, 2006). 
Peritoneal mesothelioma: is a neoplasm arising from mesothelial cells 
lining the peritoneal cavity. Treatment approaches have evolved toward 
aggressive cytoreductive surgery and perioperative intraperitoneal 
chemotherapy, but the prognosis still remain very poor with major 
studies reporting median survivals consistently under a year (Turner K, 
2012). 
Wilms’ tumour (WT): WT or nephroblastoma is a paediatric malignancy 
of the kidney, and one of the most common solid cancers of childhood. 
WT is typically composed of a combination of epithelial, mesenchymal, 
and/or blastemal cells. Nephrectomy represents the established curative 
modality (Beckwith, 1983).  

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Telomere maintenance mechanisms in clinical tumours. 
While telomerase presence has been screened in a wide variety of 
cancerous and non-cancerous tissue types, the prevalence of the ALT 
phenotype has not yet been clearly determined, since the currently 
available assays for ALT are complicated for screening a large number 
of clinical samples. In fact, whereas telomerase positive (TA+) tumours 
can be identified unequivocally by detecting the enzyme’s activity, the 
identification of ALTpositive (ALT+) cancers has been thus far based on 
telomere restriction fragment analysis and APB detection, two methods 
that display a suboptimal rate of concordance. On the basis of available 
data, ALT mechanisms seem to be frequently present in tumours of 
mesenchymal and neuroepithelial origin (Cesare AJ, 2010; Henson JD, 
2010), with respect to carcinomas (Henson JD, 2010). Such evidence 
suggests that cell type-specific mechanisms can favor the activation of 
the ALT versus telomerase, and vice versa, during tumourigenesis and 
may reflect a tighter regulation of telomerase in normal mesenchymal 
and neuroepithelial than in epithelial cells (Henson JD, 2010). 
At present, scanty information is available regarding the molecular 
pathways leading to the activation of a specific TMM in tumours. The 
mechanisms by which telomerase activity is regulated in human tumours 
have been extensively investigated. Evidence suggests that the altered 
expression of specific oncogenes and tumour suppressor genes is 
related to reactivation of the enzyme (Deng Y, 2008; Shay JW 2006). In 
addition, multiple steps for regulation of the enzyme have been unveiled. 
In particular, telomerase expression is strictly controlled at the 
transcriptional and post-transcriptional/translational level, and an 
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association between the overexpression of hTERT and the deregulated 
expression of a specific microRNA (miR-138) has been recently 
demonstrated in human anaplastic thyroid carcinoma cell lines (Mitomo 
S, 2008). As regards the ALT phenotype, although it is thought to be 
driven by a recombination--based mechanism, factors that can act as 
the main engine of the ALT pathway have not yet been identified. 
However, in the attempt to unveil candidate ALT genes, it has been 
shown that the telomere associated proteins (i.e., TRF1, TRF2, TIN2, 
RAP1) and the MRE11/RAD50/NBS1 complex (Jiang WQ, 2007, Zhong 
ZH, 2007) are essential for APB formation, indicating that they are 
probably required to sustain the ALT mechanism. It has also been 
reported that epigenetic modifications could influence which TMM is 
activated in different cancer cells. Specific epigenetic alterations within 
the chromatin environment of the hTR and hTERT promoters have been 
reported to correlate with the expression of hTR/hTERT in normal, TA+ 
and ALT+ cells (Atkinson SP, 2005). 
An interesting aspect related to TMM and tumour biology is whether 
telomerase and ALT confer different properties to tumour cells in vivo. It 
has been demonstrated that hTERT may affect cellular functions other 
than telomere length (Bollmann FM, 2008), and although telomerase 
and ALT appear to be equivalent in their ability to support 
immortalization, their contribution to tumour growth and survival may 
differ. 
Several studies have been carried out to investigate the prognostic 
implications of TMMs in clinical tumours. Reported data indicate that the 
association between prognosis and telomerase expression is not so 
straightforward in human tumours (Hiyama E, 2003). Whereas some 
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studies reported that increased telomerase activity/expression is related 
to a poor prognosis in different tumour types (Hiyama E, 2003), such an 
association was not confirmed by other studies, probably as a 
consequence of different assay conditions, data analysis and patient 
selection, thus making it difficult to draw a general conclusion on the role 
of telomerase in cancer prognosis. However, the prognostic significance 
of ALT mechanisms seems to be strictly dependent on tumour type. 
Specifically, it has been demonstrated that patients with ALT+, high-
grade glioblastoma multiforme (GBM) have significantly longer survival 
than those with ALT-negative tumours (Hakin-Smith V, 2003). In 
contrast, a poor prognosis characterizes patients with ALT+ (and TA+) 
osteosarcomas compared with patients with tumours lacking any known 
TMM (Ulaner GA, 2003). In addition, it has been reported that ALT is a 
strong determinant of an unfavorable outcome in liposarcoma patients 
(Costa A, 2006), whereas it failed to significantly affect the clinical 
outcome of patients with diffuse malignant peritoneal mesothelioma 
(Villa R, 2008). Differences in TMM-specific genetic alterations might 
explain the differences observed in the prognosis of patients with 
different tumour types.  
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Aims of the project. 
A limitless proliferative potential is one of the hallmarks of tumour cells 
and can be achieved through the activation of telomere maintenance 
mechanisms (TMM), which rely on telomerase reactivation or, 
alternatively, on recombination-based processes known as alternative 
lengthening of telomeres (ALT). To date, the molecular basis that lead to 
the activation of TMM during tumourigenesis are poorly understood but 
several lines of evidence indicate that complex signaling networks might 
be involved. Since telomerase activity has been detected in most 
tumours of epithelial origin and ALT is more frequently expressed in 
tumours of mesenchymal and neuroepithelial origin, it could be 
hypothesized that cell type-specific mechanisms — which are still 
unknown — may favor the activation of the different TMM during 
tumourigenesis. 
Another interesting aspect related to TMM and tumour biology is 
whether telomerase and ALT confer different properties to tumour cells 
in vivo, in terms of biological aggressiveness. In this context, 
controversial results have been obtained about the clinical relevance of 
TMM, whose prognostic role seems to be dependent on tumour 
histotype. This scenario could be, at least in part, the consequence of 
the lack of standardized methods to properly classify tumours with 
respect to their TMM status. 
Since a substantial fraction of tumours of mesenchymal origin utilizes 
ALT, they represent a very interesting model to study the molecular 
pathways involved in the activation of TMM. In particular, the knowledge 
of the specific factors/pathways by which the two known TMMs are 
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differentially regulated in different tumour histotypes of mesenchymal 
origin might be important for a better understanding of the pathogenesis 
of these malignancies and for the identification of new therapeutic 
targets. 
By taking advantage of the in-house availability of a large collection of 
tumour specimens with an associated clinical and patho-biological 
database, our studies were aimed at:  
i) Extending the knowledge about the prevalence and the 
prognostic significance of the two known TMMs (TA and ALT) 
in different soft-tissue sarcoma histotypes (MPNST, 
leiomyosarcoma) and mixed origin tumours (Wilms’ tumour); 
ii) Comparing the available methods to assess ALT mechanisms 
in human solid tumours and define the most suitable 
biomarker;  
iii) Analyzing the molecular pathways differentially expressed as 
a function of the different TMM operating in the tumour, using 
microRNA expression profiles in subsets of TA-positive and 
ALT-positive tumours of mesenchymal origin (including 
MPNST, and malignant peritoneal mesotheliomas);
iv) Verifying the relevance of putative TMM-related miRNAs by 
functional analysis in a human mesenchymal tumour cell line. 
Specifically, miRNA involvement in cancer-related pathways, 
such as proliferation and TMMs activation was assessed.
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Main results
In summary, with our studies, we are able to provide information on: 
i) the prevalence and prognostic relevance of TMMs in MPNST. 
In particular, at least one TMM is present in 61% of the 
MPNST with TA and ALT being present in a comparable 
fraction of tumours. Survival analyses suggested TA as 
an indicator of poor disease-specific survival. (main 
results available in this session, whole unpublished 
manuscript available in Part II, page 127)  
ii) the prevalence and prognostic relevance of TMMs in 
leiomyosarcoma, in which ALT proved to be the more 
frequently expressed mechanism. Also in this tumour
type, TMM presence (in particular ALT) proved to 
negatively affect patients’ prognosis. (manuscript in 
preparation, main results available in this session, page 35)  
iii) the prognostic relevance of ALT in a series of liposarcoma 
patients as a function of the characteristic 
(heterogeneous telomeres versus APB presence) used to 
classify the tumour, identifying APB presence as the 
most suitable marker for ALT (main results reported in this 
session, whole published manuscript “Venturini L et al., BMC 
Cancer 2010, 10:254” available in Part II, page 59)
iv) the presence, for the first time, of ALT mechanisms in Wilms’ 
tumour (main results reported in this session, whole 
published manuscript “Venturini L et al., GCC 2011 Oct; 
50(10):823-9” available in Part II, page 108)  
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v) miRNAs potentially involved in TMM regulation in tumours of 
mesenchymal origin. (preliminary results reported in this 
session, page 42) 
_________________________________________________Lorenza Venturini
33 
i) Telomere maintenance mechanisms in malignant 
peripheral nerve sheath tumours. 
Whole unpublished manuscript available in Part II, page 127, Venturini 
et al.: Telomere maintenance mechanisms in malignant peripheral nerve 
sheath tumours: expression and prognostic relevance.
The study aimed at investigating the prevalence of the two known 
telomere maintenance mechanisms (TMMs), telomerase activity (TA) 
and alternative lengthening of telomeres (ALT), and assessing their 
prognostic relevance in malignant peripheral nerve sheath tumours 
(MPNST). In 57 specimens obtained from 49 patients with MPNST (35 
sporadic and 14 neurofibromatosis type 1-related), TA was determined 
using the telomeric repeat amplification protocol and ALT was detected 
by assaying both ALT-associated promyelocytic leukaemia bodies (APB) 
and terminal restriction fragment (TRF) length distribution. TA or ALT (as 
detected by the presence of APB) alone was found in 24.6% or 26.3% of 
the lesions, respectively, whereas 6 cases (10.5%) were TA+/ALT+. A 
concordance between APB and TRF results in defining the ALT status 
was observed in 44 of 57 cases (77.2%; P<0.0001). TA was found to be 
more frequently expressed in samples from patients with 
neurofibromatosis type 1-related MPNST than in those with sporadic 
disease (60% vs. 29.4%, P=0.087). In the overall series, TA proved to 
be prognostic for 5-year disease-specific death (Hazard Ratio, 3.78; 
95% CI, 1.60-8.95; P=0.002). These findings held true even when 
adjusted for the concomitant presence of neurofibromatosis type 1 
syndrome (Hazard Ratio, 4.22; 95% CI, 1.804-9.874; P=0.001) and 
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margin status after surgery (Hazard Ratio, 5.78; 95% CI, 2.19-15.26; 
p<0.001). Conversely, ALT failed to significantly affect clinical outcome 
of MPNST patients either using APB expression (Hazard Ratio,1.25; 
95% CI 0.54-2.89; P=0.605) or TRF distribution (Hazard Ratio 0.57; 
95% CI 0.17-1.96; P=0.375) as the detection approach. Our results 
indicate for the first time that both known TMMs, TA and ALT, are 
present in MPNST and differentially affect patient prognosis. 
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Tab.1: Leiomyosarcoma patients characteristics 
ii) Telomere maintenance mechanisms in 
leiomyosarcoma (unpublished results). 
A total of 137 leiomyosarcoma frozen specimens from 116 adult patients, 
were available for TA and ALT analysis (Table 1).  
All the patients have been followed and treated at the Istituto Nazionale 
Tumouri of Milan from 1990 to 2008 and underwent different surgical 
procedures according to disease presentation. The median age was 56 
years (range 26-78) and the median follow-up for the entire group, as of 
February 2011, was 81 months. The TMM phenotype has been 
investigated on the overall case series by assessing the presence of 
APBs for assaying tumours for ALT, as well as by verifying the presence 
of telomerase activity by TRAP assay. 
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Twenty-five of 137 (18.2%) specimens were classified as TA+ based on 
positive TRAP results and more than half of cases (72/137, 52.6%) were 
classified as ALT+; among these, only 3 lesions were defined as 
ALT+/TA+, due to the concomitant expression of APBs and TA, and 
about a third (31.4%) of the lesions did not express any known TMM 
(Tab.2). 
total 
137  lesion 
TA+/ALT+ TA+/ALT- TA-/ALT+ TA-/ALT- 
3 (2.2%) 22 (16.0%) 69 (50.4%) 43 (31.4%) 
Tab. 2: TMM prevalence in leiomyosarcoma. 
In this study we also analysed the relevance of the two different known 
TMM on disease specific survival of the patients, who underwent 
surgery followed by different treatment modalities including radiotherapy 
and/or chemotherapy, according to the Institute guidelines. The 
presence of at least one TMM significantly affect patient prognosis (after 
6 years of follow-up: TMM+ vs. TMM-, hazard ratio, 5.99; 95% Cl 1.42-
25.35; P=0.015). Specifically, TA proved to be prognostic for 3-year 
disease-specific survival but such a prognostic value was not maintained 
at 6 years of follow-up (At 6 years: TA+ vs. TA-, HR, 2.15; 95% Cl, 0.86-
5.38 P = 0.102). By counterpart, after 3 years, ALT-positive patients 
showed a lower although not statistically significant probability of being 
alive, and such a trend reached statistical significance at longer follow-
up period (At 6 years: ALT+ vs. ALT-, HR, 2.55; 95% Cl, 1.03-6.30; P= 
0.043) (Figure 9). 
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TA+ vs TA-, HR, 2.15; 95% Cl, 0.86-5.38 P = 0.102      ALT+ vs ALT-, HR, 2.55; 95% Cl, 1.03-6.30; P= 0.043
Figure 9 : prognostic relevance of TMM in leiomyosarcoma patients. Disease-
specific survival at 6 years of follow-up. 
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iii)  Prognostic relevance of ALT-associated markers in 
liposarcoma: a comparative analysis  
Whole published article available on Part II, page 59: Venturini et al. 
Prognostic relevance of ALT-associated markers in liposarcoma: a 
comparative analysis. BMC Cancer 2010, 10:254  
Characteristics of ALT-positive tumour cells include an extreme 
heterogeneity of telomere length, as well as the presence of APBs, and 
different assays have been developed and alternatively used to screen 
human tumour specimens for the occurrence of ALT. 
In a previous paper from our group we reported how the presence of 
ALT in liposarcoma negatively affected patients’ prognosis (Costa A, 
2006). In this study we comparatively analysed the prognostic relevance 
of ALT in a monoinstitutional series of 85 liposarcoma patients as a 
function of the characteristic (heterogeneous telomeres vs. APB 
presence) used to classify the tumour, with the final aim to identify the 
most suitable ALT marker. We determined ALT status on each 
liposarcoma specimen by using both APB detection and telomere length 
analysis. Overall, 27 (31.8%) lesions were defined as ALT+ based on 
the presence of APB, whereas 24 (27.5%) samples were classified as 
ALT+ on the basis of TRF length distribution. A concordance between 
APB and TRF results in defining a specimen as ALT+ or ALT- was found 
in 66 of 85 cases (77.6%; kappa=0.469; 95%CI, 0.265-0.672; 
P<0.0001). Specifically, 16 lesions (18.8%) were defined as ALT+ and 
50 (58.8%) were scored as ALT- with both detection methods. As 
regards the remaining lesions, 11 were defined as ALT+ on the basis of 
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APB expression but did not show a TRF length distribution consistent 
with an ALT phenotype, and 8 were scored as ALT+ on the basis of TRF 
analysis but showed a very low percentage of APB-expressing tumour 
cells (from 0.01 to 0.2%). The prognostic significance of TMM was 
analysed on the overall series of 85 patients. When a tumour was 
defined as ALT+ according to at least one method (APB or TRF), ALT 
proved to be prognostic for 10-year disease-specific survival (ALT+ 
versus ALT-, 45.5% vs. 71.1%; HR, 2.38; 95% CI, 1.15-4.90; P=0.019), 
and such a prognostic value was maintained and strengthened at 15 
years of follow-up (ALT+ versus ALT-, 25.3% versus 71.1%; HR, 2.76; 
95%CI, 1.36-5.06; P=0.005). These results held true also when APB 
expression was used as the only parameter to classify tumours for ALT. 
Specifically, the APB presence proved to be an indicator of increased 
mortality at both 10 years (HR, 2.14; 95% CI, 1.04-4.41; P=0.040) and 
15 years (HR, 2.54; 95%CI, 1.27-5.11; P=0.009) of follow-up. 
Conversely, at 10 years of follow-up, patients with a tumour defined as 
ALT-positive on the basis of TRF length distribution showed a lower 
although not statistically significant probability of being alive (HR, 1.77; 
95% CI, 0.84-3.73; P=0.130). Such a trend reached statistical 
significance at 15 years (HR, 2.14; 95% CI, 1.06-4.34; P=0.035). The 
incomplete overlapping of the TRF and APB results may be due to the 
different liposarcoma histological subtypes and this heterogeneity may 
result in a slight difference on the time-dependence of each assay to 
provide significant prognostic information. Overall, APB may be more 
appropriate than TRF pattern to assay ALT in tumours because they can 
be detected in both frozen and formalin-fixed, paraffin-embedded 
tumour samples as well as in needle biopsies or cytology specimens. 
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iv) Telomere maintenance mechanisms in Wilms’ tumour 
Whole published article available on Part II, page 108: Venturini et al. 
Telomere maintenance in Wilms tumour: first evidence for the presence 
of alternative lengthening of telomeres mechanism. Genes 
Chromosomes and Cancer. 2011 Oct;50(10):823-9. 
To extend our knowledge about the prevalence of ALT 
mechanisms in human tumours, we took advantage of a collaboration 
with the Paediatric Oncology Unit of the Istituto Nazionale dei Tumouri. 
In particular, we investigated the presence of ALT in Wilms Tumour 
(WT), a paediatric malignancy of the kidney and one of the most 
common solid cancers of childhood composed of a combination of 
epithelial, mesenchymal and blastemal cells. We investigated ALT in 34 
WT samples from 30 patients by using both APB detection and the 
assessment of terminal restriction fragment (TRF) length distribution. In 
parallel, telomerase activity was determined by TRAP assay. Based on 
APB expression, ALT was detectable in 5 samples as the sole TMM and 
in 6 samples in association with telomerase. Seventeen samples only 
expressed TA and in 6 cases no known TMM was appreciable. 
Expression of the catalytic component of telomerase hTERT was found 
in all TA+ specimens and in 5/11 of TA- cases, confirming that the 
presence of TERT mRNA is necessary but not sufficient to obtain an 
active form of the enzyme. The presence of TA was more frequently 
observed in tumours from untreated patients compared to samples 
obtained from patients who underwent preoperative chemotherapy 
(P=0.042), while the presence of APB proved to be unrelated to 
previous treatment. Results of TRF length distribution were available in 
_________________________________________________Lorenza Venturini
41 
32 cases, and a concordance between APB and TRF data in defining 
the ALT phenotype was found in a valuable percentage of cases (81%). 
The study provided the first evidence of the presence of ALT in 
approximately one-third of WT and indicated that in a small but defined 
fraction of cases (about 15%) ALT could be the only TMM supporting the 
development of WT. 
Telomere maintenance mechanisms in mesenchymal tumours_______________
42 
v) Identification of miRNAs differentially expressed as a 
function of the TMM operating in the tumour. 
We performed miRNA expression profiling of peritoneal mesothelioma 
and MPNST samples by using the Illumina human V2 miRNA chip, 
which contains 1,146 assays, covering more than 97% of the miRNAs 
described in the miRBase database v12.0 (Sanger Institute). For this 
step we extracted high-quality RNA using Trizol reagent® that was then 
converted to cDNA by standard methods. Our aim was to identify 
specific miRNAs differentially expressed as a function of the TMM 
operating in the tumour. Specifically, we performed miRNA expression 
profiles of 29 MPNST and 50 peritoneal mesothelioma specimens that 
have been already screened for TMM during the past years. The 50 
peritoneal mesotheliomas expressed TMMs as follows: 22 cases 
TA+/ALT-, 9 cases TA-/ALT+, 16 cases TA-/ALT- and 3 cases 
TA+/ALT+ (Supplementary table 1).  
The first classification allowed us to divide samples on the basis of 
telomerase expression, irrespectively of the ALT status, in order to 
determine which miRNAs could be potentially involved in TA regulation 
in peritoneal mesothelioma. We found a signature of 84 miRNAs 
differentially expressed in TA+ vs. TA- samples (p<0.05) 
(Supplementary Table 2). We then divided mesothelioma specimens on 
the basis of ALT expression, irrespectively of TA status, defining a list of 
61 miRNAs differentially expressed between ALT+ vs. ALT- tumours 
(Supplementary Table 3). Similarly, we analysed data from miRNA 
expression profiles of MPNST samples. The tumours were classified on 
the basis of TMM as follows: 10 cases TA+/ALT-, 5 cases TA-/ALT+, 10 
cases TA-/ALT-, 4 cases TA+/ALT+ (Supplementary table 4). 
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The comparison between telomerase posive and telomerase negative 
cases generated a signature of 32 miRNA significantly differentially 
expressed (p<0.01) (Supplementary Table 5). We then compared ALT-
posive and ALT-negative cases, generating a signature of 15 miRNA 
differentially expressed between the two classes (p<0.05) 
(Supplementary Table 6). 
MiRNA expression profiles will be carried out also from a subset of the 
leiomyosarcoma samples we screened for TMM and these results will 
be analysed and compared to those obtained in mesotheliomas and 
MPNSTs. Through the screening of tumour specimens of different 
histotypes, we want to assess the expression of specific miRNA 
signatures in ALT+ and TA+ tumours independently of the histologic 
origin. 
Gene expression analyses will be carried out on the tumour types 
considered and already characterized for TMM (peritoneal 
mesothelioma, MPNST and leiomyosarcoma) with an Agilent-based 
gene expression platform. To this purpose, we will use total RNA that we 
already extracted from these tumour specimens using Trizol Reagent 
(Invitrogen). Data generated from miRNA and gene expression profiles 
will be integrated to identify possible miRNA/target gene interactions 
involved in the regulation of TMM. This analysis will help us to find a 
putative connection between TMM-associated miRNAs and the targets 
they regulate. In addition, the identification of TMM-associated genes 
and miRNAs, as surrogate markers of ALT+ and TA+ phenotypes, will 
help to correctly classify tumours according to TMM status, allowing to 
overcome the misclassification bias introduced by the current available 
detection methods.
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Ongoing results 
 To get further insight the regulation of TMM, we selected some of 
the miRNAs potentially involved in telomerase activity regulation and 
validated their expression by quantitative RT-PCR using TaqMan® 
MicroRNA. We then choosed miR380* (Supplementary Figure 1, Part III) 
for functional validation since it proved to be significantly down-regulated 
in telomerase positive mesothelioma specimens and in a telomerase 
positive peritoneal mesothelioma cell line already available and well 
characterized in our laboratory (STO cell line, Zaffaroni N, 2007). 
To unravel if miR380* could play a specific role in telomerase regulation 
and in cellular pathways relevant in the tumourigenic process, we 
restored miR-380* levels in STO cell line. Ectopic expression of miR-
380* was pursued by transfection of its synthetic precursor (Pre-miRTM
Precursor Molecules, Ambion). Transfection efficiency was evaluated by 
using 6-carboxyfluorescein-labeled microRNA (data not shown). 
A 20nM concentration proved to be effective in restoring miR-380* 
expression in STO cells, as assessed by end-point RT-PCR 3 days 
after transfection, while miR-380* levels remained undetectable in cells 
exposed to the lipidic vehicle alone (not shown) or transfected with a 
negative control oligomer (preNeg) (Figure 10).      
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 Ct 
(miR-380*) 
Ct 
(endogenous control) 
∆Ct P 
(Sudent’s t-test) 
UNT 34.8±1.2 24.5±0.03 10.4±1.23  
pre-Neg 36.4±0.6 24.6±0.02 11.7±0.54 0.14  
Pre-miR-380* 17.6±0.2 26.9±1.05 -9.33±1.1 0.0012 3.7×10-5
Figure 10: expression of miR-380* (72hs post transfection). Expression of 
miR380* is significantly higher in transfected cells with respect to negative 
control-transfected cells  (PRE NEG). Measurement was performed by qRT-
PCR. RQ=relative quantity, UNT=untransfected cells, PRE NEG=cells 
transfected with negative precursor, 380*=cells transfected with pre-miR-380*. 
RNU48 was used as PCR endogenous control. 
Ectopic miR-380* expression in STO cells induced perturbations of cell 
growth. Specifically, we observed an appreciable cell growth impairment 
in miR380*-transfected cells, which exhibited significantly longer 
population doubling time than those transfected with control microRNA 
(Figure 11). These results suggest that miR-203 could inhibit the 
proliferation of STO cell. 
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Figure 11. vital counting in each week after transfection using Trypan Blue 
Solution 0,4%.. P<0.05. Population Dubling time PD=Log10(harvested 
cells/seeded cells)/Log102. Obtaining the number of replication in each week. In 
the following weeks PD are added to the previous one.  P<0.05. 
The ectopic expression of miR380* induced appreciable morphological 
changes in transfected cells starting from the first week after transfection 
and becoming more and more evident in the following weeks. 
Specifically, we observed changes usually associated with the 
acquisition of an epithelial phenotype, with a decreasing fraction of cells 
with elongated shape and the appearance of large, flattened, polygonal-
shaped cells (Figure 12).
Weeks     0    1    2    3    4    5    6    7    8
Weeks      2       3       4        5        6       7       8 
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Figure 12. Morphology changes of pre-miR-380*-transfected cells. Pre-
miR-380*-transfected cells progressively lose their original elongated shape 
and became more rounded and flattened. 
Our data from miRNA expression profiles of peritoneal mesothelioma 
specimens showed miR-380* as significantly down-regulated in 
telomerase positive tumours. We then supposed that the reduced cell 
growth could be due, at least in part, to the occurrence of any telomere 
dysfunction related to the ectopic expression of miR-380*. For instance 
we measured telomere length of the transfected cell populations by 
Southern Blot analysis of Telomere restriction Fragments (TRF) (Villa R, 
2000) (for further details see materials and methods in Part II, published 
papers). After 8 weeks of transfection, the expression of miR-380* and 
the cell growth impairment were accompanied by a small but significant 
Weeks 
3 
4 
8 
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telomere shortening (Figure 13). Specifically, the mean TRF was 5,12 
Kb in pre-Neg-transfected cells and 4,71 Kb in pre-miR-380*-transfected 
cells. 
   
We then argued that the observed telomere shortening in miR-380*-
expressing cells could be due to a direct or indirect role of miR380* in 
telomerase activity regulation. TRAP assay showed a strong inhibition of 
telomerase activity in miR380*-transfected cells after 8 weeks of 
treatment when compared to the cells transfected with negative 
precursor and to untreated cells. Specifically, a quantitative analysis 
showed a reduction of about 90% of telomerase activity in pre-miR-380*-
treated cells when compared to pre-neg treated samples. (Figure 14).  
Figure 13. Telomere Restriction Fragment 
lenght analysis by Southern blot. Unt: 
untreated cells, Pre Neg: cells transfected 
with negative precursor, Pre-miR-380*: cells 
trasfected with miR-380* precursor, U2OS: 
osteosarcoma cell line and GM 847: human 
fibroblasts included as control. 
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Figure 14. TRAP assay for telomerase activity. 0.1 ug of protein was used 
for each sample in this assay. The signal intensity for each lane is normalized 
with the corresponding ITAS signal. TSR8=positive control, HI=heat inactivated 
negative control, ITAS=internal amplification standard.  
To further verify whether mir-380* modulation can affect telomere 
dynamic, we will evaluate also eventual changes in terms of APB 
expression changes in the APB-negative STO cell line treated with miR-
380* synthetic precursor. 
Putative target genes for miR380* TA-associated miRNA will be found 
using the available miRNA target prediction databases, such as 
miRanda, TargetScan and PicTar, allowing us to identify potential 
molecular targets related to telomerase regulation.
Week 2 Week 8
UNT 1.0±0.3 1.2±0.07 
pre-NEG 1.0±0.12 1.05±0.01 
pre-380* 0.1±0.004 0.06±0.001 
Weeks of trasfection:               2                8 
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Conclusions and future perspectives 
With respect to human tumours of epithelial origin, our data show the 
relatively low frequency of telomerase activity in soft tissue sarcomas, 
such as MPNST and leiomyosarcoma as discussed in the present 
thesis, and in liposarcoma as reported in previous works of our group, 
implicating that telomerase reactivation is an important, although not 
crucial event involved in the progression of such malignancies.  
By counterpart, the evidence that in liposarcoma and MPNST the 
frequency of tumours that activate ALT is comparable with that of 
tumours that express telomerase, and in leiomyosarcoma approximately 
half of the cases use ALT as TMM, opens important questions about the 
mechanisms that may determine which TMM becomes activated in 
individual tumours and the requirement for telomere maintenance during 
the development of these malignancies.  
From our data we can address an important issue for the clinical use of 
telomerase inhibitors related to the choice of the best patient population. 
The reported evidence that many solid tumours express the ALT 
phenotype instead of telomerase and, as a consequence, are not likely 
to be affected by telomerase inhibitors, suggests that TMM status should 
be determined in individual patients before starting any hypothetical anti-
telomerase treatment. 
Moreover, since ALT and telomerase may coexist in the same tumour, it 
is also conceivable that treatment of TA-positive tumours with 
telomerase inhibitors could exert a potent selection pressure, leading to 
the emergence of subpopulations of ALT-positive tumour cells refractory 
to telomerase inhibitors. 
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On the other hand, we found that a significant percentage of tumours 
(about 40% of MPNSTs, a third of leiomyosarcoma and about 15% of 
WT) possessed no apparent TMM despite being informative for the 
different assays, suggesting that the presence of a constitutively active 
TMM is not a stringent requirement for these malignancies, or, 
alternatively, that these tumours use a mechanism that has not yet been 
identified. Moreover, such a lack of any known TMM, is in accord with 
experimental data suggesting that TMM acquisition is not always 
required for malignant transformation of normal human cells. However, 
the possibility that the lack of TMM expression observed in a high 
percentage of the tested MPNSTs may be related, at least in part, to the 
sensitivity of the assays used cannot be excluded. 
In this way, the identification of TMM-associated miRNAs, as surrogate 
markers of ALT+ and TA+ phenotypes, will help to correctly classify 
tumours according to TMM status, eventually allowing to overcome the 
classification biases introduced by the current available detection 
methods and, possibly, provide new potential indicators of prognosis.  
In addition, the validation of candidate TMM-associated miRNAs will be 
instrumental to discover new cancer-related targets, paving the way for 
the development of innovative anticancer therapeutics, which could be 
tailored to patients as a function of the specific TMM, also taking into 
account, the lack of reliable therapeutic options other than complete 
surgery. 
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Abstract 
Background: Most cancers maintain telomeres by activating 
telomerase but a significant minority, mainly of mesenchymal origin, 
utilize an alternative lengthening of telomeres (ALT) mechanism. 
Methods: In this study we comparatively analyzed the prognostic 
relevance of ALT in a monoinstitutional series of 85 liposarcoma patients 
as a function of the marker (ALT-associated promyelocytic leukemia 
bodies (APB) versus heterogeneous telomeres) used to classify the 
tumor. 
Results: Independently of the detection approach, ALT proved to be a 
prognostic discriminant of increased mortality, although the prognostic 
relevance of the two markers appeared at different follow-up intervals (at 
10 years for APB and 15 years for telomeres). 
Conclusions: Overall, we confirmed ALT as an indicator of poor clinical 
outcome in this disease and provide the first evidence that the sensitivity 
of the ALT predictive power depends, at least in part, on the method 
used. 
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Background 
A hallmark of cancer cells is their limitless proliferative potential, which is 
sustained by the activation of a telomere maintenance mechanism 
(TMM) [1]. In a high percentage of human tumors (> 85%), proliferation 
dependent telomere shortening is counterbalanced by the synthesis of 
telomeric DNA, which is catalyzed by telomerase [2]. However, in few 
cancers that lack telomerase, an alternative lengthening of telomeres 
(ALT) mechanism is used [3]. There may be more than one ALT 
mechanism, but in at least some ALT-positive human cancer cells 
telomere length is maintained by recombination mediated replication of 
telomeric DNA [4]. Characteristics of ALT-positive tumor cells include an 
extreme heterogeneity of telomere length, with telomeres ranging from 
very short to extremely long within the same cell, as well as the 
presence of subnuclear structures termed ALT-associated promyelocytic 
leukemia (PML) bodies (APB), which contain telomeric DNA, telomere 
binding proteins and proteins involved in DNA recombination and 
replication [5]. Assays to detect telomere length and APB have been 
developed and alternatively used to screen human tumor specimens for 
the occurrence of ALT. Available results indicate that ALT is more 
common in tumors of mesenchymal and neuroepithelial origin, including 
osteosarcomas [6], soft tissue sarcomas [7] and glioblastoma multiforme 
[8], and that the presence of ALT has prognostic significance that 
depends on tumor type. Specifically, in liposarcoma ALT proved to be a 
strong prognostic discriminant of increased mortality [9], whereas in 
glioblastoma the presence of ALT was associated to a better patient 
survival [8], suggesting that the prognostic relevance of ALT presumably 
reflects the distinct set of genetic changes that are associated to the 
activation of ALT in a given tumor type. In the present study, we 
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comparatively analyzed the prognostic relevance of ALT in a 
monoinstitutional series of liposarcoma patients as a function of the 
characteristic (heterogenoeus telomeres versus APB presence) used to 
classify the tumor, with the final aim to identify the most suitable marker. 
Methods 
Study population 
Samples from 85 liposarcomas, all from adult patients (36 women and 
49 men; median age, 52 years; range, 18-91) treated with a curative 
intent at the Istituto Nazionale Tumori of Milan from December 1986 to 
November 2003 were available for TMM analysis (Additional file 1, Table 
S1). The specimens, which represent a subset of a larger case series 
already characterized for TMM (Costa et al, 2006), were consecutive 
with respect to the availability of frozen tissue and adequate 
clinicopathologic and follow-up information. Twenty-two patients 
presented with primary tumors and 63 with recurrent disease (59 
localregional recurrences and 4 metastases), and they underwent 
different surgical procedures according to disease presentation. The 
median follow-up for the entire group, as of December 2008, was 118 
months. During the follow-up, 36 patients died for cancer-related causes 
(30 within 10 years, another 2 from 10 to 15 years, and 4 after 15 years). 
Postoperative treatment was given when there was a high risk of 
recurrence: 18 patients were submitted to radiotherapy, 8 to 
chemotherapy, and 5 to radio-chemotherapy according to the treatment 
protocols of the multidisciplinary Soft Tissue Sarcoma Group of the 
Institute. This study was approved by the Institutional Review Board of 
the Institute, and all patients provided written informed consent to 
donate to the Institute the leftover tissue after diagnostic procedures. 
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Detection of APB, telomere length and telomerase activity (TA) 
Tumor tissue was sampled by a pathologist at the time of surgery and 
flash frozen. A fragment of about 100 mg was cut from each lesion and 
further subdivided for APB detection, DNA extraction (for telomere 
length assessment) and protein extraction (for TA assay). APB were 
assayed by combined PML immunofluorescence and telomere 
fluorescence in situ hybridization [10]. PML was detected with anti-PML 
mouse antibody (Dako Cytomation; Glostrup, Denmark) plus anti-mouse 
FITC-labeled goat antibody (Sigma; St. Louis, MO). Telomere 
fluorescence in situ hybrization (FISH) was performed by denaturing 
slides together with 5'labeled Cy3-(5'CCCTAA3')3 PNA probe (Applied 
Biosystems, Framingham, MA) for 3 min at 80°C and h ybridizing for 3 hs 
at room temperature. Slides were washed and counterstained with 4'6- 
Diamino-2-phenylindole (DAPI). Images were captured on a Nikon 
Eclipse E600 fluorescence microscope using ACT-1 (Nikon, Tokyo, 
Japan) image analysis software and processed using Adobe Photoshop 
Image Reader 7.0 software. APB status was determined according to 
previously defined criteria: the presence of an APB was defined by the 
localization of a telomeric DNA focus within a nuclear PML body, 
sections were scored as APB+ if they contained APB in 0.5% of tumor 
cells and a tumor was considered ALT+ when at least one section was 
APB+. A set of criteria was used to determine the APB status of tumor 
section. An APB was considered to be present only when the telomeric 
DNA fluorescence within a PML body was more intense than that of 
telomeres, and a cell was not considered to contain APB if more than 
25% of the co-localized foci occurred outside the nucleus. To avoid false 
negatives, at least 2,000 tumor nuclei were examined, and the assay 
was repeated in the presence of negative results. 
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Telomere length was assessed by pulsed-field gel electrophoresis as 
previously described [11]. ALT status was determined by calculating 
whether the mean, variance, and semi-interquartile range of the terminal 
restriction fragment (TRF) length distribution were greater than 16 kb, 
1,000 kb2, and 4 kb, respectively. Tumors were classified as ALT+ when 
two of three or three of three of these criteria were met for unimodal or 
bimodal TRF length distributions, respectively. Statistical analysis of 
TRF length distributions was done with Telometric software [12]. TA was 
measured by the telomeric repeat amplification protocol (TRAP) [13], 
with the TRAPeze kit (Intergen, Oxford, UK) as outlined in Costa et al. 
[9]. 
Data analysis 
The agreement between APB and TRF data was assessed by kappa 
statistics. The clinical end point of the study was cancer-related survival, 
and the time of its occurrence was computed from the date of first 
diagnosis to the time of death, or censored at the date of the last 
recorded follow-up for living patients. Survival curves were estimated by 
means of the Kaplan-Meier product limit method [14], and the Cox 
proportional hazards model [15] was used to calculate the hazard ratios 
(HR) and their confidence interval (CI). SAS software (SAS Institutes, 
Inc., Cary, NC) was used to perform statistical calculations, and a two-
sided P value 0.05 was considered statistically significant. 
Results and discussion 
ALT status was determined on each liposarcoma specimen by using 
both APB detection and telomere length analysis (Fig. 1). Overall, 27 
(31.8%) lesions were defined as ALT+ based on the presence of APB, 
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whereas 24 (27.5%) samples were classified as ALT+ on the basis of 
TRF length distribution.  
Figure 1 ALT assays in liposarcomas. A) APB assay: combined PML 
immunofluorescence and telomere fluorescence in situ hybridization (FISH) in 
a frozen section of an ABP-positive liposarcoma. Indirect immunofluorescence 
was used for the PML protein (FITC label, green stain). Telomere FISH was 
done using a Cy3-conjugated telomeric peptide nucleic acid probe (red stain). 
Nuclei were counterstained with 4',6-diamidino-2-phenylindole (blue stain). The 
foci of telomeric DNA that co-localize with PML represent APB. B) TRF 
southern blot analysis. Telomere length distribution of a representative series 
of liposarcomas. The lengths of telomeres in ALT-positive cells typically range 
from < 3 to > 50 kb. ALT-negative cells typically have a more homogeneous 
distribution of telomere length and a shorter average length than ALTpositive 
cells. 
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A concordance between APB and TRF results in defining a specimen as 
ALT+ or ALTwas found in 66 of 85 cases (77.6%; kappa = 0.469; 95% 
CI, 0.265-0.672; P < 0.0001). Specifically, 16 lesions (18.8%) were 
defined as ALT+ and 50 (58.8%) were scored as ALT- with both 
detection methods. As regards the remaining lesions, 11 were defined 
as ALT+ on the basis of APB expression but did not show a TRF length 
distribution consistent with an ALT phenotype, and 8 were classified as 
ALT+ on the basis of TRF analysis but showed a very low percentage of 
APB-expressing tumor cells (from 0.01 to 0.2%). 
The incomplete overlapping of the results obtained with the two methods 
is not surprising. In fact, while the APB assay allows the analysis of 
individual tumor cells, the TRF pattern could be misleading due to the 
admixture of normal and tumor cells present in the specimen. However, 
it has been recently shown by Jeyapalan et al. [16] that some 
telomerase-negative liposarcomas without APB express recombination-
like activity at the telomere, suggesting that the incidence of ALT, as 
defined solely on the basis of APB expression, could be underestimated. 
Thirty of 85 (35.3%) liposarcoma specimens were classified as TA+ 
based on positive TRAP results. Among these, 6 and 8 lesions were 
defined as ALT+/TA+ based on the expression of APB or on TRF length 
distribution, respectively, thus confirming the possibility that the two 
TMM coexist in the same lesion as previously reported also for other 
tumor types [3,17,18]. The prognostic significance of TMM was analyzed 
on the overall series of 85 patients. TA alone did not prove to be 
associated with disease-specific mortality (120 months: TA+ versus TA-, 
62.0% versus 60.0%; HR, 0.91; 95% CI, 0.43-1.95; P = 0.814) (180 
months: 62.0% versus 48.5%; HR, 0.80; 95% CI, 0.38-1.70; P = 0.566), 
whereas significant results were obtained for ALT. Specifically, when a 
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tumor was defined as ALT+ according to at least one method (APB or 
TRF), ALT proved to be prognostic for 10-year disease-specific survival 
(ALT+ versus ALT-, 45.5% versus 71.1%; HR, 2.38; 95% CI, 1.15-4.90; 
P = 0.019), and such a prognostic value was maintained and 
strengthened at 15 years of follow-up (ALT+ versus ALT-, 25.3% versus 
71.1%; HR, 2.76; 95% CI, 1.36-5.06; P =0.005). These results held true 
also when APB expression was used as the only parameter to classify 
tumors for ALT. Specifically, the APB presence proved to be an indicator 
of increased mortality at both 10 years (HR, 2.14; 95% CI, 1.04-4.41; P 
= 0.040) and 15 years (HR, 2.54; 95% CI, 1.27-5.11; P = 0.009) of 
follow-up (Fig. 2A). Conversely, at 10 years of follow-up, patients with a 
tumor defined as ALT-positive on the basis of TRF length distribution 
showed a lower although not statistically significant probability of being 
alive (HR, 1.77; 95% CI, 0.84-3.73; P = 0.130). Such a trend reached 
statistical significance at 15 years (HR, 2.14; 95% CI, 1.06-4.34; P = 
0.035) (Fig. 2B). These results held true even after adjustment for TA. In 
fact, the prognostic significance of APB expression was evident both at 
10 (HR, 2.16; 95% CI, 1.03-4.51; P = 0.041) and at 15 years (HR, 2.53; 
95% CI, 1.24-5.15; P= 0.011) of follow up, whereas TRF length 
distribution provided significant information only at 15 years of follow-up 
(HR, 2.11; 95% CI, 1.04-4.23; P = 0.038). 
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Figure 2 Probability of disease-specific survival as a function of ALT, 
detected by APB presence (A) or TRF length distribution (B), according 
to the criteria reported in Methods, in liposarcoma patients. 
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Conclusions 
In agreement with previously published results based on APB detection 
[9], we confirmed ALT as a prognostic discriminant of increased 
mortality in liposarcomas and provide the first evidence that sensitivity of 
the ALT predictive power depends, at least in part, on the marker (APB 
expression versus TRF length distribution) used. Notwithstanding the 
good agreement observed between the two assays in defining the ALT 
phenotype, they do not precisely identify the same subset of patients, 
conversely to that observed in glioblastoma multiforme, where a 
complete agreement in the results of the two assays was observed [10]. 
The incomplete overlapping of the TRF and APB results may be due to 
the different liposarcoma histological subtypes and this heterogeneity 
may result in a slight difference on the time-dependence of each assay 
to provide significant prognostic information. Overall, APB may be more 
appropriate than TRF pattern to assay ALT in tumors because they can 
be detected in both frozen and formalin-fixed, paraffin-embedded tumor 
samples - as we recently reported in this tumor type [19] - as well as in 
needle biopsies or cytology specimens. However, additional studies 
aimed at comparing the prognostic significance of results obtained with 
APB and TRF assays in other tumor types are warranted to provide 
reliable indications on the most appropriate ALT-related marker to be 
used for prognostic purposes. 
Abbreviations 
ALT: Alternative lengthening of telomeres; TMM: Telomere maintenance 
mechanisms; APB: ALT-associated Promyelocitic leukaemia bodies; 
TRF: Terminal restriction fragment; TA: Telomerase activity; HR: Hazard 
ratio. 
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Table S1: patients and tumors characteristics. 
Case
Age 
(years)
Gender Sample
Histological 
subtype
Site Post-treatment Status TA APB TRF
1 91 M R DE extremities no DO + - -
2 35 M R MY extremities no AWD + - -
3 64 F R PL extremities no DOD - + +
4 55 F R PL extremities no DOD - + +
5 38 M P RC extremities RT DOD - + +
6 47 F R RC extremities no DOD + - -
7 41 M R MY extremities RT NED + - -
8 43 F M MY extremities CTRT DOD + - -
9 58 F R DE retroperitoneum no DOD - - -
10 76 F P DE retroperitoneum no DOD - - -
11 49 F R DE retroperitoneum RT DOD - - -
12 42 F R RC retroperitoneum CT DOD + - +
13 33 F R MY retroperitoneum RT DOD + - -
14 73 M R DE retroperitoneum CT DOD - + +
15 49 M M RC extremities no AWD + - -
16 62 F R RC extremities no DOD + - -
17 41 M M MY extremities no DOD + - +
18 39 M R DE retroperitoneum CT DOD + - -
19 43 M M RC extremities no AWD + - +
20 36 M R WD retroperitoneum no DOD - - -
21 51 M R DE trunk no NED - + +
22 27 M R MY extremities no DOD - - +
23 52 M P WD extremities no NED - - -
24 46 F R WD extremities no NED - - -
25 62 M P WD extremities no NED - - -
26 50 M P WD retroperitoneum no AWD - - -
27 61 M R WD retroperitoneum CT DOD - - -
28 41 M R DE retroperitoneum no AWD - - -
29 81 M R PL extremities no DOD - + -
30 57 M R DE retroperitoneum CT+RT DOD - - -
31 65 M R WD extremities RT NED - - -
32 64 F R MY extremities no DO - - -
33 57 M R PL retroperitoneum no DOD - + -
34 68 M R WD retroperitoneum no AWD - + +
35 37 F R WD trunk no NED - - -
36 68 M P WD retroperitoneum no NED - - -
37 60 F R DE extremities RT NED - - -
38 47 F R WD retroperitoneum no AWD - - -
39 53 F R DE retroperitoneum no DOD + + +
40 40 F R MY extremities RT NED - - -
41 23 F R WD extremities no NED - - -
42 53 M R DE retroperitoneum CT DOD - - -
43 65 F R WD extremities no NED - + +
44 68 M R WD retroperitoneum no NED - - -
45 59 M R WD retroperitoneum no DOD + - -
46 47 M P RC extremities RT NED + - -
47 72 F R DE extremities no DOD - + +
48 59 F P DE retroperitoneum CT DOD - + -
49 43 M R RC extremities CT+RT AWD + - -
50 80 M R DE extremities RT DOD - + +
51 62 F R DE retroperitoneum no DOD + + -
52 79 M P WD extremities no NED - - -
53 50 F R DE retroperitoneum CT DOD + - -
54 63 M R WD retroperitoneum no DO - - -
55 53 F R MY extremities no NED + - +
56 55 M R RC extremities no NED + - -
57 56 F R DE extremities no DOD - + +
58 42 F P RC extremities RT NED - - -
59 56 M R DE extremities no DOD - + +
60 52 M R PM trunk no NED - + -
61 53 M R MY extremities no NED - + +
62 57 F R WD extremities no NED - - -
63 53 M R DE retroperitoneum no DOD - + +
64 34 F P MY extremities RT NED - - -
65 42 M R WD extremities no NED - - -
66 55 M P MY extremities no NED - - -
67 62 M R WD extremities no NED - - -
68 71 M P MY trunk RT DO - + +
69 61 F R RC extremities RT DOD + - -
70 54 F P RC extremities no NED + + -
71 45 F R DE retroperitoneum no DO - - -
72 51 F P MY extremities no DOD + - +
73 45 M P RC extremities no NED + - +
74 44 F R RC extremities CT+RT DOD - + -
75 47 M R RC extremities RT NED + + -
76 31 M P RC extremities RT NED + - -
77 62 M R RC extremities no AWD + + -
78 49 M P RC trunk CT+RT NED + + +
79 30 F P RC extremities RT NED - - +
80 33 M R MY extremities no DOD - + -
81 32 F P MY extremities RT NED - + -
82 18 M P MY extremities no NED - - -
83 41 M P RC extremities CT DOD - - -
84 42 F R MY extremities RT NED + - -
85 34 M R MY extremities no AWD + - -
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M= male, F= female, P= primary, R= local recurrence, M= metastasis, WD= 
well-differentiated, DE= dedifferentiated, MY= myxoid, RC= round-cell, PL= 
pleomorphic, CT= chemotherapy, RT= radiotherapy, DOD= dead of disease, 
DO= dead of other causes, AWD= alive with disease, NED= not evidence of 
disease, TA= telomerase activity, APB= ALT-associated promyelocytic 
leukaemia bodies, TRF= terminal restriction fragments. 
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Telomeres as targets for anticancer therapies 
Marco Folini†, Lorenza Venturini, Graziella Cimino-Reale & Nadia 
Zaffaroni 
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Experimental Oncology and Molecular Medicine, Milan, Italy 
Introduction: The limitless replicative potential of cancer cells relies on 
telomere integrity (which is guaranteed by a complex interaction 
between several specialized proteins and telomeric DNA) and the 
activation of specific mechanisms for telomere length maintenance. Two 
mechanisms are currently known in human cancer, namely telomerase 
activity and the alternative lengthening of telomere pathway. 
Expert opinion: In this review, we summarize the available data 
concerning the therapeutic strategies proposed thus far and the current 
challenges posed for the development of innovative telomere-based 
therapeutic approaches with broad-spectrum anticancer activity and for 
their translation into the clinical setting. 
Areas covered: Due to their essential role in tumor cell proliferation, 
telomere maintenance mechanisms have become extremely attractive 
targets for the development of new anticancer interventions. Although 
numerous efforts have been made to identify specific approaches to 
interfere with telomere maintenance mechanisms in human cancers, the 
only molecule currently tested in clinical trials is the oligonucleotide 
GRN163L. However, a growing body of evidence suggests that 
interfering with telomeres, through the direct targeting of telomeric G-
quadruplex structures, may be a valuable antitumor therapeutic strategy, 
independent of the specific telomere maintenance mechanism operating 
in the tumor.  
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Keywords: ALT mechanisms, bisantrene, G4-ligands, G-quadruplex, 
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Article highlights.  
• Telomeres are specialized DNA--protein structures located at the end of 
eukaryotic chromosomes. Their functions are crucial to guarantee 
genome stability (by protecting chromosomes from degradation, end-to-
end chromosomes fusion, and unsuitable recombination) and to limit 
cell proliferation (mitotic clock). 
• A hallmark of cancer cells is their limitless proliferative potential, which 
is at least in part sustained by the activation of a telomere maintenance 
mechanism (TMM). 
• Two TMMs are currently known in human cancer, namely telomerase 
activity and the alternative lengthening of telomeres (ALT) pathway. 
Due to their essential role in tumor cell proliferation, such mechanisms 
have become extremely attractive targets for the development of new 
anticancer interventions. 
• Due to its selective reactivation in many human tumors, the possibility 
to interfere with telomerase expression or functions represents a useful 
strategy for the development of specific anticancer therapies. 
• Data obtained from preclinical studies concerning the effects of 
telomerase inhibition have provided compelling arguments to indicate 
that the enzyme is a well-validated cancer target. However, the only 
telomerase inhibitor currently tested in clinical trials is the 
oligonucleotide GRN163L (Imetelstat). 
• Interfering with telomeres, through the direct targeting of telomeric G-
quadruplex structures (G4), could be a valuable and innovative 
antitumor therapeutic approach due to the possibility to interfere with 
unlimited cell proliferation independently of the specific TMM operating 
in the tumor (telomerase versus ALT). Several molecules able to 
stabilize telomeric G4 structures has been identified thus far. 
• At the preclinical level, it was shown that telomeric G4 ligands efficiently 
interfered with the growth of a variety of tumor models. In addition, they 
have shown synergistic activity in vivo when combined with 
conventional anticancer drugs. Despite such well-documented 
antitumor and chemosensitizing effects in preclinical models, none of 
the available telomeric G4 ligands has entered clinical trials. 
• The development of suitable methodological approaches to precisely 
define G4 structures and to dissect their role in normal versus tumor 
cells may provide important clues for the synthesis of novel and more 
specific G4 ligands for the development of broad spectrum, telomere-
based anticancer therapeutic strategies. 
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1. Introduction 
1.1 The telomere 
Telomeres are specialized DNA--protein structures located at the ends 
of eukaryotic chromosomes. Their functions are crucial to protect the 
genome from degradation, end-to-end chromosome fusion and 
unsuitable recombination [1,2]. Human telomeric DNA consists of 
tandem repeated (TTAGGG)n sequences, on the average of about 10 
kb, with a single-stranded terminus on the 3’-oriented strand (3’-
overhang) [1]. In normal somatic cells, telomeres shorten with each 
round of cell division as a natural consequence of the inability of the 
DNA polymerase to completely replicate the chromosome ends. 
Therefore, telomere erosion imposes in normal cells a finite number of 
cell divisions, thus representing a cell-autonomous mechanism to 
prevent excessive telomere shortening and, as a consequence, genomic 
instability and malignant transformation. 
Another problem associated with the ends of linear chromosomes is that 
they must be distinguished from chromosome breaks to prevent them 
from undergoing improper repair processes. In this context, several 
proteins are involved in DNA binding, which allows telomeric DNA to fold 
back on itself, resulting in the formation of a telomere loop (t-loop) [3] in 
which the singlestrand tail can invade duplex telomeric DNA. In humans, 
telomeric DNA is associated with the shelterin protein complex [3], which 
includes telomeric-repeat binding factor 1 (TRF1) and 2 (TRF2), which 
bind to double-stranded DNA [3], and protection of telomeres 1 (POT1), 
that binds directly to single-stranded DNA [3]. These proteins directly or 
indirectly interact with other components of shelterin, such as TRF1-
interacting protein 2 (TIN2), POT1- and TIN2-organizing protein, and the 
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transcriptional repressor/activator protein RAP1 [3]. The contribution of 
RAP1 in the shelterin complex and telomere stabilization is just now 
emerging [4], and recent evidence suggests a role in repressing non-
homologous end joining through interaction with TRF2 [5]. 
In addition to the shelterin complex, mammalian telomeres interact with 
other proteins, including factors involved in DNA replication, repair and 
recombination [3,6]. The unique architecture, high GC content, and 
multi-protein association create particularly stable protein--DNA 
complexes that are a challenge for telomere replication and 
recombination [7]. As a consequence, diverse mechanisms have 
evolved to accommodate these problems at the telomeric level, 
including i) the presence of shelterin protein components that facilitate 
fork progression, control 3’-overhang formation and cap the telomere 
after replication [6] and ii) the activation of DNAdamage checkpoints 
(relying on ataxia-telangectasia-mutated (ATM) or ATM and Rad3-
related signaling pathways) that help to overcome replication constraints 
by activating repair mechanisms upon telomere replication and 
uncapping [3,6]. 
In addition, members of four helicase families -- RecQ, Pif1, FANCJ, and 
DNA2 -- are known to have roles in telomere biology [7-9]. Specifically, 
DNA helicases of the RecQ family act on atypical DNA structures, such 
as intermediates of homologous recombination, stalled sites of 
replication forks and the G-quartet structure of telomere DNA (discussed 
in detail below). Furthermore, mutations or perturbation of telomere 
activities of RecQ-like helicases (i.e., BLM, Bloom’s syndrome; WRN, 
Werner’s syndrome; RECQL4, Rothmund-Thomson’s syndrome), as 
well as FANCJ (Fanconi’s anemia) helicase can lead to telomere 
dysfunction and genome instability and cause inherited human diseases 
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characterized by increased cancer susceptibility and premature aging 
[7,8]. In addition, BLM and WRN interact with the telomere specific 
proteins POT1, TRF1 and TRF2 and their helicase activity is modulated 
by these interactions [8,9]. Recent findings also indicate that the 
heterotrimer CST (Cdc13-Stn1-Ten1), found in budding yeast, is present 
in mammal cells, where it seems to contribute to telomere capping [10]. 
In addition, Snm1B/Apollo, a member of the SNM1/PSO2 family of 
nucleases, has been reported to be implicated in telomere protection 
and replication via its interaction with TRF2 [11]. Therefore, proper 
telomere protection might result from the cooperation between shelterin 
and CST, and a new model is now emerging in which TRF2 and Apollo 
facilitate the replication of telomeres by relieving topological constraints 
from telomeric DNA [10,11]. Altogether, these telomere-associated 
proteins cooperate to determine telomere replication, protection and 
stability, thus contributing to the integrity and dynamics of chromosome 
ends.  
1.2 Telomere maintenance mechanisms in cancer 
A hallmark of cancer cells is their limitless proliferative potential, which is 
at least in part sustained by the activation of a telomere maintenance 
mechanism (TMM). Telomere maintenance is essential for the 
transformation of most human cancer cells, and the activation of a TMM 
is crucial to escape a crisis and allow cells to become immortalized. 
In a high percentage of human tumors (> 85%), proliferation-dependent 
telomere shortening is counterbalanced by the synthesis of telomeric 
sequences by telomerase [12]. The enzyme is an RNA-dependent DNA 
polymerase that adds multiple copies of the TTAGGG motif to the end of 
the telomeric G-strand. The core enzyme consists of the RNA 
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component human telomerase RNA (hTR, which provides the template 
for the synthesis of telomeric DNA) and the reverse transcriptase 
catalytic subunit human telomerase reverse transcriptase (hTERT) [13]. 
Although hTR and hTERT are sufficient to obtain telomerase activity in 
vitro, additional protein components such as dyskerin and telomerase 
Cajal body protein 1 are required for the correct assembly and trafficking 
of the enzyme in human cells [12,14]. In addition to its role in 
maintaining chromosome ends through the regulation of telomere 
length, telomerase has been recently implicated in providing growth-
promoting properties to tumor cells, independently of its catalytic activity 
[15]. Whereas hTR has been found to be ubiquitously expressed in all 
human tissues, the catalytic component of telomerase hTERT has been 
proposed as a cancer-specific target, since it is almost exclusively 
expressed in tumor compared with normal tissues [12]. However, there 
are human tumors (~15%) lacking telomerase that maintain telomere 
length by a pathway known as the alternative lengthening of telomeres 
(ALT) mechanism [16]. Characteristics of ALT cells include an extremely 
heterogeneous telomere length distribution, ranging from very short to 
more than 50 kb, and the presence of subnuclear structures termed 
ALT--associated promyelocytic leukemia (PML) bodies (APB) [16]. PML 
bodies are normal nuclear domains of unknown function that contain the 
PML protein. In ALT cells, a subset of the PML bodies contains 
telomeric chromatin (telomeric DNA and the telomere binding proteins 
TRF-1 and TRF-2) [16]. Another specific feature of ALT mechanisms is 
C-circles (self-priming circular telomeric DNA), which may represent 
molecular intermediates of the ALT mechanisms and whose specificity 
for assessing ALT activity in biological samples has recently been 
demonstrated [17]. The prevalence of the ALT phenotype in human 
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cancers has not yet been clearly determined, since the currently 
available assays for ALT are complicated for screening a large number 
of clinical samples. In fact, whereas telomerase positive (TA+) tumors 
can be identified unequivocally by detecting the enzyme’s activity, the 
identification of ALTpositive (ALT+) cancers has been thus far based on 
telomere restriction fragment analysis and APB detection, two methods 
that display a suboptimal rate of concordance. The lack of standardized 
methods for ALT determination has major implications for the 
classification of ALT+ tumors. In this context, instability at the 
minisatellite MS32, usually associated with ALT activation in human 
cancer cell lines [18], and the presence of complex telomere mutations 
have been described in liposarcomas, which have recombination-like 
activity at telomeres in the absence of APBs [19], suggesting that the 
incidence of ALT may be underestimated using conventional assays. 
Concerning newer detection methods, the C-circle assay has proven to 
be a sensitive and specific test for ALT [17,20], even though its reliability 
on a large set of clinical specimens has not yet been confirmed. 
On the basis of available data, ALT mechanisms seem to be frequently 
present in tumors of mesenchymal and neuroepithelial origin [16,20], as 
well as in tumors of mixed origin, such as Wilms’ tumors (L Venturini, 
pers. commun.), with respect to carcinomas [20]. Such evidence 
suggests that cell type- specific mechanisms can favor the activation of 
the ALT versus telomerase, and vice versa, during tumorigenesis and 
may reflect a tighter regulation of telomerase in normal mesenchymal 
and neuroepithelial than in epithelial cells [20]. At present, scanty 
information is available regarding the molecular underpinnings leading 
to the establishment of a specific TMM in tumors. The mechanisms by 
which telomerase activity is regulated in human tumors have been 
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extensively investigated. Evidence suggests that the altered expression 
of specific oncogenes and tumor suppressor genes is related to 
reactivation of the enzyme [21,22]. In addition, multiple steps for 
regulation of the enzyme have been unveiled. In particular, telomerase 
expression is strictly controlled at the transcriptional and post-
transcriptional/translational level, and an association between the 
overexpression of hTERT and the deregulated expression of a specific 
microRNA (miR-138) has been recently demonstrated in human 
anaplastic thyroid carcinoma cell lines [23]. As regards the ALT 
phenotype, although it is thought to be driven by a recombination--based 
mechanism, factors that can act as the main engine of the ALT pathway 
have not yet been identified. However, in the attempt to unveil candidate 
ALT genes, it has been shown that the telomere associated proteins 
(i.e., TRF1, TRF2, TIN2, RAP1) and the MRE11/RAD50/NBS1 complex 
[24,25] are essential for APB formation, indicating that they are probably 
required to sustain the ALT mechanism. A number of studies [8,9] also 
suggested that the BLM and WRN RecQ-like helicases play important 
roles in recombination-mediated mechanisms of telomere elongation in 
ALT cells. It has also been reported that epigenetic modifications could 
influence which TMM is activated in different cancer cells. Specific 
epigenetic alterations within the chromatin environment of the hTR and 
hTERT promoters have been reported to correlate with the expression of 
hTR/hTERT in normal, TA+ and ALT+ cells [26]. 
An interesting aspect related to TMM and tumor biology is whether 
telomerase and ALT confer different properties to tumor cells in vivo. It 
has been demonstrated that hTERT may affect cellular functions other 
than telomere length [15], and although telomerase and ALT appear to 
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be equivalent in their ability to support immortalization, their contribution 
to tumor growth and survival may differ.  
Several studies have been carried out to investigate the prognostic 
implications of TMM in clinical tumors. Reported data indicate that the 
association between prognosis and telomerase expression is not so 
straightforward in human tumors [27]. Whereas some studies reported 
that increased telomerase activity/expression is related to a poor 
prognosis in different tumor types [27], such an association was not 
confirmed by other studies, probably as a consequence of different 
assay conditions, data analysis and patient selection, thus making it 
difficult to draw a general conclusion on the role of telomerase in cancer 
prognosis. However, the prognostic significance of ALT mechanisms 
seems to be strictly dependent on tumor type. Specifically, it has been 
demonstrated that patients with ALT+, high-grade glioblastoma 
multiforme (GBM) have significantly longer survival than those with ALT-
negative tumors [28]. In contrast, a poor prognosis characterizes 
patients with ALT+ (and TA+) osteosarcomas compared with patients 
with tumors lacking any known TMM [29]. In addition, it has been 
reported that ALT is a strong determinant of an unfavorable outcome in 
liposarcoma patients [30], whereas it failed to significantly affect the 
clinical outcome of patients with diffuse malignant peritoneal 
mesothelioma [31]. Differences in TMM-specific genetic alterations 
might explain the differences observed in the prognosis of patients with 
different tumor types. In this context, it has been reported that ALT+ 
liposarcomas show significantly higher levels of genome instability and 
loss of heterozygosity than their TA+ counterparts [32]. Furthermore, 
whole-genome profiling has revealed genetic alterations that further 
distinguish ALT+ from TA+ liposarcoma lesions [32].
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2. Targeting telomeres
2.1 Telomerase inhibitors 
Telomerase attracted attention after its discoverers E.H. Balckburn, C. 
Greider and J. Szostak won the 2009 Nobel Prize in Physiology and 
Medicine. Since its discovery in the early 1980s, telomerase has been 
considered a potential drug target [33]. Due to its selective reactivation 
in most human tumors, the possibility to interfere with telomerase 
expression and/or functions has been considered a useful strategy for 
the development of effective anticancer therapies [12,22,34]. Several 
approaches (Figure 1) have been pursued with the aim of interfering i) 
with the enzyme’s catalytic activity. A variety of nucleoside analogs and 
non-nucleoside compounds have been exploited to inhibit telomerase 
activity [12]. Among them, BIBR1532, a non-competitive inhibitor that 
binds to a site in the enzyme which is distinct from those for 
deoxyribonucleotides and the DNA primer, is one of the most potent 
small molecule inhibitors of telomerase discovered thus far [35]; ii) with 
the expression of the enzyme’s core subunits hTR and hTERT by 
antisense-based approaches using chemically modified oligonucleotides 
(e.g., phosphorothioates, 2’-O-modified RNA oligomers, 2’,5’-
oligoadenylates, N3’P5’ phosphoramidates and peptide nucleic acids), 
catalytic RNAs, such as ribozymes, and small interfering RNAs [12]; iii) 
with signaling pathways responsible for post-transcriptional/translational 
modifications of telomerase (e.g., small molecules) [12,34]. At present, 
the most promising telomerase ‘drug candidate is GRN163L or 
imetelstat, a lipid palmitate derivative of the N3’P5’ 
thiophosphoramidate oligomer GRN163 targeting hTR [36]. GRN163L 
does not exhibit antisense activity, but rather acts as an antagonist of 
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telomerase by binding with high affinity and specificity to the template 
region of hTR [36]. Its effects have been thoroughly investigated in 
many preclinical studies, both in cell cultures and xenografted tumors. 
Recently, GRN163L has been shown to efficiently inhibit telomerase 
activity in prostate-tumor-initiating cells [37] as well as in GBM tumor-
initiating cells, where it increases the therapeutic efficacy of radiation 
and temozolomide, two common therapeutic approaches for GBM 
patients [38]. It was demonstrated in an orthotopic GBM mouse model 
[38] that imetelstat efficiently penetrates the blood brain barrier and 
inhibits telomerase activity. In addition, it was reported to prevent lung 
metastases in vivo [39], probably as a consequence of its hTR-
independent anti-adhesive properties [40]. Thus far, imetelstat has been 
evaluated in seven Phase I and Phase I/II clinical trials for several 
cancers, including solid and hematological tumors, either as a single 
agent or in combination regimens [41]. The primary objectives of such 
studies are safety, tolerability and determination of the maximum 
tolerated dose. Preliminary data have shown imetelstat to be well 
tolerated [42], with a toxicity profile consistent with that reported for other 
oligonucleotides [36]. 
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Figure 1. Telomerase inhibitors. Schematic representation of the most widely 
exploited strategies to interfere with the expression and function of human 
telomerase in cancer cells (see text). Colored box: imetelstat (or GRN163L) is 
the only telomerase inhibitor currently employed in clinical trials. hTERT: 
Human telomerase reverse transcriptase; hTR: human telomerase RNA.
Available data indicating that interference with telomerase expression 
and/or function leads to increased sensitivity of cancer cells to 
conventional anticancer drugs and radiation [12,22,34] corroborate the 
notion that telomerase represents a promising anticancer target also for 
the design of new combination therapies. In this context, combination 
studies with imetelstat plus paclitaxel and bevacizumab, imetelstat plus 
paclitaxel and carboplatin, or imetelstat plus bortezomib ± 
dexamethasone have been activated in breast cancer, NSCLC and 
multiple myeloma, respectively [41]. Although clinical trials have been 
activated, there are no available data yet on the efficacy of imetelstat in 
cancer patients [36].  
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2.2 Interference with telomere-associated proteins 
Studies on shelterin components have contributed knowledge about 
their specific role in the regulation of telomere structure and dynamics. 
Specifically, most of the data gathered thus far have shown that the 
shelterin complex acts as a physical cap to protect the ends of 
chromosomes from being recognized as natural double-strand breaks, 
thus distinguishing normal ends from double-strand breaks and avoiding 
the activation of DNA damage checkpoints [3]. The notion that the 
deprotection of telomeres results in the activation of a DNA-damage 
response (DDR) gained support from the evidence that DDR factors, 
such as tumor protein p53 binding protein 1 (53BP1), histone gH2AX, 
meiotic recombination 11 (Mre11) and phospho-ataxia telangectasia 
mutated (ATM), can localize at uncapped telomeres and form cytological 
structures referred to as telomere dysfunction-induced foci [3]. The main 
protective role has been assigned to TRF2. The inhibition of TRF2 
through the overexpression of a dominant-negative mutant of the protein 
(TRF2DBDM), able to heterodimerize with the endogenous TRF2 and to 
block its binding to telomeric DNA [3], resulted in a high frequency of 
chromosome end-to-end fusions as a consequence of 3¢--overhang 
loss, the activation of DNA ligase IV-dependent non-homologous end 
joining, and the ATM/p53-mediated DDR pathway, ultimately leading to 
cell death in several in vitro models [3]. In addition, mouse models 
knocked-out for TRF2 showed embryonic lethality, and cells derived 
from TRF2- and p53-null embryos were characterized by loss of 
telomere protection and massive increase in end-to-end fusions [43]. 
Overall, these findings indicate TRF2 to be an early component of the 
DDR system, and the assessment of its delocalization from telomeres by 
chromatin immunoprecipitation or combined immunofuorescence has 
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become a useful approach to check early events related to the induction 
of telomeric DNA damage. Furthermore, a possible role of TRF2 in 
mediating drug resistance of cancer cells can be envisaged based on 
the observation that RNAi-mediated inhibition of TRF2 expression 
partially reversed the phenotype of multidrug-resistant variant SGC7901 
gastric cancer cells [44]. The TRF1 homodimer within the shelterin 
complex binds double-stranded telomeric repeats, helping to localize 
shelterin to telomeres [3]. It has been demonstrated that long-term 
overexpression of the protein in the telomerase positive HT1080 cell line 
resulted in a gradual and progressive telomere shortening, whereas 
telomere elongation was induced by expression of a dominant-negative 
TRF1 mutant that inhibited binding of endogenous TRF1 to telomeres 
[45]. As TRF1 did not affect the expression of telomerase, it has been 
suggested that the binding of TRF1 controls telomere length in cis by 
inhibiting the action of telomerase at the ends of individual telomeres 
[45]. Thus, it is critical that the levels of TRF1 are properly controlled. 
Two major pathways regulate TRF1 localization and abundance. TRF1 
is poly--ADP--ribosylated by tankyrase 1 leading to TRF1 release from 
telomeres and subsequent ubiquitination by stem cell factor SCFFbx4, 
and hence degradation by the proteasome [45,46]. In addition, TIN2 
suppresses TRF1 polyubiquitination by sequestering its degradation 
motif from recognition by SCFFbx4 when both are assembled in the 
shelterin complex [46]. The dynamic regulation of TRF1 by tankyrase 1, 
SCFFbx4 and TIN2 appears to play an important role in telomere 
homeostasis maintenance. As a consequence, interference with any of 
these mechanisms may represent a useful approach to affect cancer cell 
growth. In this context, it has been demonstrated that the longterm 
inhibition of tankyrase 1 poly-ADP-ribosylation activity enhanced 
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progressive telomere shortening induced by a telomerase inhibitor and 
hastened cell death in human cancer cells [46]. Furthermore, given the 
specificity of the TRF1--Fbx4 binding interface, it is possible to envision 
the development of selective small molecule inhibitors that specifically 
perturb interaction between SCFFbx4 and TRF1 [46]. 
Dysfunctional telomeres can also be induced by interference with the 
expression of other components of shelterin. For instance, the role of 
hPOT1 in protecting telomeres has been evaluated in human cells 
exposed to anti-hPOT1 siRNAs. Specifically, hPOT1 knockdown 
resulted in the induction of apoptosis as a consequence of telomere 
dysfunction, increased expression of p53 and B-cell leukaemia/ 
lymphoma 2 associated X protein (Bax), and concomitant decrease of B-
cell leukaemia/lymphoma (Bcl-2) levels in breast cancer cells [47]. A 
marked increase in the levels of telomere-induced foci was also 
observed in HeLa cells following hPOT1 knockdown [48]. In addition, 
experimental findings showing that deletion of the pot1 gene in mice 
resulted in chromosomal instability, and increased telomere 
recombination further suggested a role of POT1 in carcinogenesis [43]. 
An alternative approach currently under investigation to target telomeres 
in cancer cells involves the expression of mutated hTR with an altered 
template sequence [49-52]. These mutant templates complex with 
hTERT in tumor cells and direct the addition of mutant telomeric repeats, 
which are predicted to disrupt binding of shelterin components [52]. 
Treatment with such mutant templates rapidly induces DNA damage at 
telomeres and results in cell growth inhibition and apoptosis induction in 
hTERT-expressing cancer cells, independently of p53 and pRb status 
[50,51]. Recently, ATM has been reported to be a key mediator of the 
dysfunctional telomere response mediated by MT-hTer-47A, an hTR 
Telomere maintenance mechanisms in mesenchymal tumors______________________

mutant template that directs the addition of TTTGGG repeats instead of 
wild-type human telomeric repeats [52]. In this context, ATM-depleted 
melanoma and bladder cancer cells showed increased clonogenic cell 
survival and a reduced rate of cell death following MT-hTer-47A 
treatment compared with ATM-competent controls [52]. 
2.3 Telomeric G-quadruplex ligands
Under physiological ionic conditions, G-rich sequences within nucleic 
acids are capable of generating a four-stranded helical structure, known 
as G-quadruplex (G4), which forms when four molecules of guanylic 
acid are present in a square planar arrangement [53]. The structures 
exhibit extensive structural polymorphism and may form intramolecular 
or intermolecular DNA strands [53]. G-quadruplex structures can be 
classified depending on the orientation of the DNA strands in parallel, 
antiparallel or a hybrid structure [53]. Interest in these structures has 
recently increased following the observation of their in vivo existence in 
oncogene promoters and telomeres [54,55], leading to the notion that 
G4 may play key roles in biological processes. Indeed, a bioinformatic 
analysis has identified 375,000 candidate sequences within the human 
genome that could form G4 structures [53]. The latter are frequently 
found in proto-oncogenes, such as c-MYC, VEGF, c-kit, hypoxia-
inducible factor (HIF)-1a and Bcl-2, rather than in tumor suppressor 
genes [53]. It has been demonstrated that G4-forming regions within the 
c-MYC promoter play a critical role in regulating expression of the gene. 
A single point mutation (which destabilizes the G4) resulted in a 
threefold increase in c-MYC basal transcriptional activity, whereas a G4-
stabilizing cationic porphyrin was able to suppress c-MYC transcriptional 
activation [53]. It has been recently reported that the hTERT core 
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promoter also contains a G-rich sequence [56]. Such consecutive G-
tracts have the potential to form multiple G4, which in turn may mask 
specific protein-1 (Sp1) binding sites, thus resulting in inhibition of 
hTERT promoter activity [56]. Telomeric DNA has received much 
attention in this regard, as single-stranded G-rich telomeric 3’-overhang 
can fold into several different intramolecular quadruplex structures that 
differ for the position of the adjacent loop regions. However, it is 
becoming clear that single-strandedness is not a prerequisite for G4 
formation. Transient destabilization of duplex DNA during transcription, 
replication, or DNA repair may be sufficient to allow G4 formation at 
many sites in the genome [53]. At the telomere level, intermolecular G4 
could play different roles in telomere--telomere associations, in the 
alignment of sister chromatids during meiosis (i.e., telomere meiotic 
bouquet), and in homologous chromosome pairing during meiosis [53]. 
In addition, telomeric G4 may cap telomeres, thus protecting them from 
inappropriate elongation by telomerase or from nucleolytic degradation 
and end-to-end fusion events. In addition, G4 may play an important role 
in inhibition of the ALT pathway. As the 3’-overhang is essential during 
the early steps of recombination, sequestration of this single stranded 
region at the ends of chromosomes into G4 could form an effective 
barrier against ALT [53]. There is evidence that G4 formation may be 
relevant also at the RNA level. Specifically, it has been reported that 
alternative splicing of a number of genes is affected by G4-forming 
sequences in pre-mRNA [57]. In this context, the G4-inducing drug 
12459, initially believed to cause telomerase inhibition, telomere 
shortening and apoptosis in cancer cells as a consequence of its binding 
to telomeric DNA, was indeed revealed to mediate the stabilization of G4 
in the pre-mRNA of hTERT, causing a shift in the hTERT splicing pattern 
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toward the production of an inactive form of hTERT [57]. In addition, a 
G-rich RNA sequence located in the 5’-untraslated region of TRF2 
mRNA has been recently reported to be capable of forming a stable G4, 
substantiating a potential translational mechanism for the 
downregulation of TRF2 [58]. Another potentially G4-forming RNA is the 
recently identified G-rich telomeric repeat-containing RNA (TERRA), 
which is transcribed from promoters located within subtelomeric regions 
and whose function in human cells still needs to be properly understood 
[59]. It has been reported that G4 structures formed by TERRA localize 
at the ends of chromosomes, suggesting a possible association 
between TERRA and telomeric DNA [59]. In this context, an extensive 
investigation about the expression levels of TERRA and its possible role 
in normal versus tumor tissues is strongly warranted. Information 
derived from such a study will help to define whether or not G4 
structures within TERRA may be a valuable target for telomere-based 
anticancer agents, especially for tumors that do not express telomerase. 
Elucidation of the crystal and solution structures of telomeric G4 has led 
to the rational development of effective G4-stabilizing small molecules 
[60]. The concept that telomeric G4 can represent a therapeutic target 
was established by the observation that a group of disubstituted 
amidoanthraquinones containing a planar aromatic chromophore could 
inhibit telomerase activity [61]. Since then, the number of known G4 
ligands has grown rapidly (Table 1). 
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Table 1. Summary of the relevant findings on G4-stabilizing agents obtained in 
human tumor experimental models. 
G4 ligand* Experimental models Biological response [Ref.]
2,6-pyridine-
dicarboxamide 
derivatives
A panel of telomerase-
positive cancer cells 
and ALT-positive 
SAOS-2 osteosarcoma 
cells
Inhibition of cell growth and induction of 
apoptosis; activation of S-phase checkpoint, 
increase in metaphase duration and 
cytokinesis defects; telomere instability 
related to end-to-end fusions and anaphase 
bridges [73]
4,5-di-substituted 
acridone
MCF7 and A549 
cancer cell lines; 
IMR90 normal 
fibroblast cell line
Acute toxicity in cancer cell lines; cell growth 
inhibition in long-term setting at subtoxic 
doses; induction of senescence; no inhibition 
of telomerase activity; no telomere 
shortening; no effect in normal fibroblasts [77]
Bisantrene derivatives 
(An1,5)
SKMel-5 melanoma 
and U2-OS osteogenic 
sarcoma cell lines
Telomerase activity inhibition; long-term cell 
growth inhibition in both telomerase- and 
ALT-positive cell lines; presence of TIFs, 
induction of senescence & autophagy [70,88]
Cryptolepine derivatives 
(SYUIQ-5)
HL-60 and K562 
leukemic cells; SW620 
colon cancer cells 
Nasopharyngeal CNE2 
and HeLa cell lines
Inhibition of c-myc promoter activity; 
reduction of hTERT, E2F1 and TRF2 
expression levels; inhibition of telomerase 
activity; telomere shortening; cell growth 
arrest and induction of senescence or 
delayed apoptosis [69,86] 
Inhibition of cell viability; induction of a 
telomere DNA damage response; induction 
of an autophagic cell death response [87]
HXDV (synthetic 
derivative of 
telomestatin)
A panel of 
normal/cancer 
telomerase- and 
ALT-positive cell lines 
Inhibition of cell growth independently of 
telomerase activity; 
M-phase cell cycle arrest; mitotic defects; 
induction of apoptosis [76]
Pentacyclic acridines 
(RHPS4)
Several experimental 
models
Inhibition of telomerase activity; acute 
cellular cytotoxicity; delayed cell growth 
arrest at subtoxic doses; cell cycle 
perturbations; reduction of telomere length or 
induction of telomere dysfunctions; 
delocalization of TRF1,TRF2 and hPOT1; 
impairment of fork progression and telomere 
processing; overexpression of WRN and 
BLM helicases; activation of an ATR-
dependent ATM response and induction of 
TIFs; activation of PARP-1; induction of 
apoptosis & senescence 
[67,72,74,75,78,80,81,91] 
Inhibition of cell growth in the ALT-positive 
GM847 skin fibroblast cell lines [78] 
Increased in vitro sensitivity to anticancer 
drugs; active as single agent in human 
xenografts of different hystotypes; in vivo 
synergistic interaction with camptothecins 
and PARP inhibitors [67,75,81,91] 
Porphyrin derivatives 
(TMPyP4)
HeLa S3 cervical and 
MiaPaCa-2 pancreatic 
cancer cell lines 
Inhibition of telomerase activity; down-
regulation of c-myc and hTERT gene 
expression [84] 
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MX-1 breast and PC-3 
prostate tumor 
xenografts 
A panel of myeloma 
cell lines
Significant decrease in tumor growth rate 
and increase in mice survival [84] 
Inhibition of telomerse activity and telomere 
shortening; reduction of cell viability after the 
first 14 days of treatment [66] 
S2T1 -- 6OTD (synthetic 
derivative 
of telomestatin)
Medulloblastoma and 
atypical 
teratoid/rhabdoid 
childhood brain cancer 
cell lines
Strong inhibition of c-myc promoter activity; 
reduced expression of c-myc and hTERT; 
dose- and time-dependent antiproliferative 
effect; c-myc-dependent telomere shortening 
after long-term treatment with subtoxic  
doses, cell growth arrest and induction 
of senescence and apoptosis [69]
Telomestatin (SOT-095) OM9;22 and K562 
leukemic cell lines; 
normal 
bone marrow CD34+ 
cells 
Inhibition of telomerase activity; long-term 
inhibition of cell growth; telomere shortening 
and dysfunctions; activation of an ATM-
dependent DNA damage response; modest 
effects on normal bone marrow cells [64] 
Enhanced sensitivity toward imatinib, 
doxorubicin, mitoxantrone & vincristine in 
K562 cells 
Tetrasubstituted 
napthalene diimides
A panel of cancer cell 
lines;  
WI38 normal fibroblast 
cell line KIT-dependent 
gastrointestinal tumor 
cell line (GIST882)
Potent cytotoxic activity in cancer cell lines; 
inhibition of telomerase activity; no toxicity in 
normal fibroblasts [82] 
Marked cell growth arrest and effective 
inhibition of telomerase activity; complete 
suppression of KIT mRNA & protein 
expression [98] 
Triazine derivatives A panel of cancer and 
normal fibroblast cell 
lines
Inhibition of telomerase activity in the 
nanomolar range; delayed cell growth arrest 
at subtoxic doses; telomere shortening and 
induction of senescence [63,65] 
Trisubstituted acridine 
(AS1410)
MCF7 breast cancer 
and A549 lung cancer 
cell lines
Growth arrest at subtoxic doses; synergistic 
activity in combination with cisplatin [93]
Trisubstituted acridine 
(BRACO-19)
DU145 prostate cancer 
cell line  
UXF1138L uterus 
carcinoma cell line and 
Xenografts 
A431 vulval carcinoma 
xenografts
Rapid inhibition of cell growth, onset of 
senescence, increased incidence of 
chromosomal fusion (partially independent of 
telomerase activity inhibition) [71] 
Decrease of hTERT expression; cell growth 
arrest after 15 days; induction of 
senescence; 96% of tumor growth inhibition; 
loss of nuclear hTERT protein expression 
and increase in atypical mitoses in 
xenografted tissues [90] 
Synergistic antitumor effect when combined 
with paclitaxel [92].
*Listed in alphabetical order. 
ALT: Alternative lengthening of telomeres; ATM: Ataxia-telangectasia mutated; ATR: 
Ataxia-telangectasia mutated and Rad3-related; BLM: Bloom’s syndrome; hTERT: 
Human telomerase reverse transcriptase; hPOT: Human protection of telomeres; 
PARP-1: Poly (ADP-ribose) polymerase 1; TIF: Telomeric-induced focus; TRF: 
Telomeric-repeat binding factor; WRN: Werner’s syndrome. 
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Features shared by many of the G4 ligands include a large flat aromatic 
surface, the presence of cationic charges, and the ability to adopt a 
terminal stacking mode. Recently, the first example of thermally induced 
non-metal-based G4 adduct formation, where a reversible binding 
process is associated with selective alkylation and stabilization of G4, 
was described by using novel G4 ligand/alkylating hybrid structures, 
tethering the naphthalene diimide (NDI) moiety to quaternary ammonium 
salts, as quinone-methide precursors [62]. These new NDI derivatives 
were shown to efficiently enhance G4 induction and to induce a 
cytotoxic effect that correlated with their DNA alkylating ability [62]. Due 
to the inability of telomerase to extend a G4-folded telomeric substrate, 
G4-interacting agents were first evaluated as telomerase inhibitors. In 
agreement with the initial paradigm for telomerase inhibition, long-term 
exposure of human cancer cells to subtoxic doses of specific G4 ligands 
induced progressive telomere shortening and replicative senescence 
(Figure 2) [63-69]. Similarly, exposure of telomerase-positive human SK-
Mel5 melanoma cells to subtoxic concentrations of the bisantrene 
regioisomer Ant1,5, identified as a G-quadruplex stabilizer and 
telomerase inhibitor by screening of a set of anthracene derivatives 
substituted with 4,5-dihydro-1H-imidazol-2-yl-hydrazonic groups at 
different positions of the aromatic system, resulted in the inhibition of 
telomerase activity, delayed antiproliferative effects, and the onset of 
senescence, thus suggesting a good selectivity window between 
antitelomerase activity and cell growth impairment [70].  
However, there is also evidence that G4 ligands are able to cause a 
short-term antiproliferative response that cannot be simply explained by 
telomerase inhibition. Specifically, the observation that the exposure of 
cancer cells to some G4 ligands caused the induction of a telomeric 
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DDR and generated telomere dysfunctions, which results in 
chromosome aberrations independently from telomerase inhibition, led 
to the proposal that the target of G4 ligands could be the telomere rather 
than telomerase [71-77]. 
Figure 2. Cellular consequences of telomere targeting by G-quadruplex 
ligands. G-quadruplex stabilizers may induce (1) long--term effects based on 
telomere erosion resulting in senescence induction and (2) short--term effects 
through telomere uncapping (human protection of telomeres 1 (hPOT1) and 
telomeric-repeat binding factor 2 (TRF2) de-localization) and induction of a 
DNA damage response, resulting in the onset of apoptosis and/or autophagy. 
Ant1,5: Bisantrene regioisomer; H2A: Histone 2A; NDI: Naphthalene diimide; 
RHPS4: 3,11-difluoro-6,8,13- trimethyl- 8H-quino[4,3,2-kl] acridinium 
methosulfate. 
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The notion that G4-stabilizing agents can inhibit the growth of ALT cell 
lines further corroborates the hypothesis that the antiproliferative effects 
of G4 ligands are largely independent of the presence of active 
telomerase. In this context, it has been demonstrated that the triazine 
derivative 115405, the pentacyclic acridine 3,11-difluoro-6,8,13-
trimethyl-8H-quino [4,3,2-kl] acridinium methosulfate (RHPS4) and the 
synthetic derivative of telomestatin HXDV (a 24-membered macrocycle 
containing six oxazole moieties and two valine residues) were able to 
inhibit the growth of SV40-immortalized human skin fibroblasts GM847, 
which maintain telomeres by the ALT pathway [65,76,78]. Similarly, the 
2,6-pyridine-dicarboxamide derivatives, the synthetic derivative HXDV 
and the bisantrene regioisomer Ant1,5 were found to induce 
antiproliferative effects in telomerase-negative/ALT-positive Saos-2 and 
U2-OS human osteogenic sarcoma cell lines [70,73,76]. In addition, it 
has been recently observed that treatment with telomestatin, a natural 
G4-interacting agent isolated from Streptomyces nanulatus, resulted in 
depletion of the topoisomerase III/BLM/TRF2 complex and disruption of 
APBs, with concomitant induction of a DDR at telomeres in the ALT-
positive MRC5-V1 lung fibroblast cell line [79]. At present, RHPS4 
seems to be the most effective G4 ligand, at least in preclinical models. 
It shows a high selectivity for G4 structures [80], and long-term exposure 
of cells to low RHSP4 concentrations causes telomere erosion and an 
irreversible growth arrest, as a consequence of the drug’s ability to 
inhibit telomerase activity at submicromolar concentrations [67,80]. At 
higher doses, RHPS4 triggers damage in cells traversing the S phase, 
as a consequence of its ability to impair fork progression and telomere 
processing. It also determines alterations of the dynamic association of 
TRF1, TRF2 and hPOT1 with telomeres [75], the overexpression of 
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Werner and Bloom helicases, the activation of an ATR-dependent ATM 
signaling pathway, and the occurrence of chromosome aberrations [75]. 
It has also been documented that RHPS4 induces the specific activation 
of poly (ADP-ribose) polymerase 1 (PARP1), resulting in the 
accumulation of several poly-ADP-ribose residues that co-localize with 
TRF1 at telomeres [81]. Recently, a series of tetrasubstituted NDI 
compounds with N--methylpiperazine end groups was evaluated as G4 
ligands [82]. They showed high affinity for telomeric G4 over duplex 
DNA and the ability to stabilize G4 with paralleltype topology, to inhibit 
the binding of hPOT1 to topoisomerase IIIa to telomeric G4 DNA, and to 
selectively induce cytoxicity in a panel of cancer cell lines [82]. In 
addition, three C-11 diamino cryptolepine derivatives, with significant 
chemical differences between the side chains, have been selected for 
anticancer drug screening in the National Cancer Institute (NCI) 
Developmental Therapeutic Program [83]. G4 binding affinity and 
selectivity studies showed that two compounds with aliphatic amine side 
chains, NSC748392 and NSC748393, are good but not selective G4 
ligands, whereas NSC748394, with an aromatic side chain, showed high 
selectivity although with decreased affinity. Again, the three compounds 
showed good in vitro antiproliferative properties at submicromolar 
concentrations, but only the NSC748393 derivative demonstrated 
significant activity in the in vivo hollow fiber assay [83]. It has been 
demonstrated that the cationic porphyrin meso-5,10,15,20-Tetrakis-(N-
methyl-4-pyridyl) porphine, Tetratosylate (TMPyP4) is able to prolong 
survival and decrease tumor growth rates in xenograft tumor models due 
to its ability to downregulate the expression levels of c-MYC (which 
harbors G-rich sequences in its promoter) and the resultant 
transcriptional repression of hTERT [84]. Similarly, the cryptolepine 
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derivative N’-(10H-Indolo [3,2-b]quinolin-11-yl)-N,N-dimethyl-propane-
1,3-diamine (SYUIQ-5) [85] was able to inhibit the c-MYC promoter and 
telomerase activity, resulting in telomere shortening and apoptosis 
induction in leukemia cells, after long-term exposure to low drug 
concentrations [86]. Conversely, at higher concentrations, SYUIQ-5 
rapidly inhibited cancer cell growth [87]. Specifically, exposure of 
nasopharyngeal carcinoma CNE2 cells and HeLa cells to high 
concentrations of SYUIQ-5 caused a quick antiproliferative effect as a 
consequence of a potent DNA damage induction, as evidenced by TRF2 
delocalization from telomeres, activation of ATM and accumulation of g-
H2AX (which co-localizes with TRF1). In addition, an increased 
expression of LC3-II as well as the evidence of a punctuate pattern of 
yellow --fluorescent-protein-tagged LC3 [87], two common markers used 
to detect autophagic activity, have been reported following exposure to 
SYUIQ-5, suggesting that the biological effects of such a G4 ligand may 
depend, at least in part, on the induction of autophagy. 
In this context, it has been recently reported that SKMel-5 melanoma 
cells exposed to Ant1,5 display morphological and biochemical features 
consistent with induction of the autophagic pathway [88]. 
3. Conclusions 
Data obtained from preclinical studies concerning the effects of 
telomerase inhibition have provided compelling arguments to indicate 
that the enzyme is a well-validated cancer target [2]. However, the 
development of therapies to selectively target telomerase in human 
tumors has been hampered in part by the lack of structural data on the 
enzyme. In this context, data on the high-resolution structure of human 
telomerase have been recently reported [13] and could provide a new 
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opportunity to screen for small molecules to modulate telomerase 
function in human cancer and to develop novel telomerase-based 
therapeutic strategies. An important issue that needs to be addressed 
for the clinical use of telomerase inhibitors is related to the choice of the 
best patient population. Evidence that many solid tumors express the 
ALT phenotype instead of telomerase [16] and, as a consequence, are 
not likely to be affected by telomerase inhibitors suggests that TMM 
status should be determined in individual patients before starting an 
anti-telomerase treatment. Moreover, since ALT and telomerase may 
coexist in the same tumor [16,20], it is also conceivable that treatment of 
TA+ tumors with telomerase inhibitors could exert a potent selection 
pressure, leading to the emergence of subpopulations of ALT+ tumor 
cells refractory to telomerase inhibitors. In this context, inhibitors that 
specifically target the ALT pathway have not been described, probably 
as a consequence of the fragmentary information concerning the 
molecular events driving such a mechanism. Based on results of a 
recent survey aimed to comparatively evaluate the expression levels of 
telomere-related proteins in normal and tumor tissues, none of these 
proteins stands out as a novel cancer-related target [89]. Taken 
together, these observations highlight the current hurdles to the rational 
design of novel agents able to target specific factors involved in the 
maintenance of telomere structure/function. Such novel agents could 
move in into clinical practice. 
At the preclinical level, it has been demonstrated that the use of 
compounds that selectively target specialized telomere structures, such 
as G4, can rapidly induce programmed cell death and activate a DDR in 
a variety of tumor models. Overall, a consistent mechanism of action 
schema is now emerging for telomeric G4 ligands in tumor cells. 
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Specifically, they can act through two interconnected pathways (Figure 
2). They may either inhibit telomerase activity by locking the single 
stranded telomere substrate into a quadruplex structure, resulting in 
long-term effects, or can trigger telomere uncapping, giving rise to short-
term effects as a consequence of the induction of telomere dysfunctions. 
In addition, G4 ligands, such as RHPS4, have been shown to be active 
in vivo as single agents [75,90,91] and displayed synergistic activity 
either in vitro or in vivo when combined with conventional anticancer 
drugs (e.g., platinum compounds, taxanes and topoisomerase I 
inhibitors), imatinib and PARP1 inhibitors [64,67,81,91-93]. However, 
despite such well-documented antitumor and chemosensitizing effects in 
preclinical models, none of the available G4 ligands is currently under 
clinical development.  
4. Expert opinion 
Interference with the limitless replicative potential of human cancer cells 
has emerged as a promising therapeutic strategy from preclinical 
studies, but telomerase-based cancer therapeutics are moving very 
slowly to the clinical setting. In fact, the only telomerase inhibitor 
currently being tested in clinical trials is the template antagonist 
imetelstat [37]. In addition, lack of knowledge about the molecular 
determinants of ALT mechanisms makes it difficult to design and 
develop therapies to selectively interfere with telomere homeostasis in 
tumors that do not express telomerase. Based on this scenario, the 
evidence that G4 structures may influence several biological processes 
other than telomere maintenance makes them an attractive target for 
broadspectrum anticancer therapies [94]. To this purpose, a precise 
definition of the structure and the role of G4 in normal and tumor cells is 
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imperative before G4-stabilizing agents can enter the clinical 
armamentarium. The development of suitable methodological 
approaches to detect G4 structures [95] as well as of innovative 
reagents, including antibodies and aptamers able to discriminate among 
the different G4 conformations [96,97], will further help to assess the 
abundance of G4 in vivo and their effects in human diseases and will 
provide important clues for the synthesis of novel ligands that 
specifically recognize these structures. An additional issue that still 
needs to be addressed for G4 ligands with respect to their ability to be 
exploited as anticancer drugs deals with their therapeutic window. The 
evidence that G4 ligands selectively impair the growth of cancer cells 
without affecting the viability of normal cells [64,76,82], together with the 
ability of these compounds to exert an antitumor activity in different in 
vivo models and to induce antiproliferative effects also in ALT cells, point 
to G4 ligands as possible drug candidates for future clinical applications. 
Furthermore, it cannot be excluded that protein composition at the 
telomere may differ, quantitatively and/or qualitatively, in normal versus 
tumor cells and that normal cells may be provided with a higher degree 
of telomere stability, thus becoming less sensitive to telomere-interacting 
agents. A therapeutic advantage regarding G4 ligands resides in the 
evidence that they may have multiple quadruplex targets. In this context, 
it has been recently reported that an NDI derivative inhibited the growth 
of gastrointestinal stromal tumor cells as a consequence of its ability to 
interact with G4 located both at the telomeric level and in the promoter 
region of the c-kit, an oncogene frequently activated in this tumor type 
[98]. There is still concern regarding the reliability of the preclinical 
models currently used to evaluate the therapeutic potential of telomere-
based therapeutics. Specifically, more sophisticated human models 
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(including three-dimensional and organotypic cultures as well as animal 
models that address the problems of tumor heterogeneity and slow 
replication of tumor stem cells) should be used to obtain a more realistic 
proof of the potential of the proposed therapeutic approaches and 
potentially ‘speed’ their translation into the clinical setting. 
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Abstract 
Unlimited proliferative potential is a hallmark of cancer, and can be 
achieved through the activation of telomere maintenance mechanisms 
(TMMs). Most tumors activate telomerase, but a significant minority, 
mainly of mesenchymal origin, uses a recombination-based, alternative 
lengthening of telomeres (ALT) mechanism. We investigated the 
presence of ALT in 34 Wilms tumor (WT) samples from 30 patients by 
using two approaches: (i) the detection of ALT-associated promyelocytic 
leukemia (PML) nuclear bodies (APBs) by combined PML 
immunofluorescence and telomere fluorescence in situ hybridization and 
(ii) the assessment of terminal restriction fragment (TRF) length 
distribution by pulsed field gel electrophoresis. 
In parallel, telomerase activity (TA) was determined by the telomeric 
repeat amplification protocol (TRAP) assay. 
Based on APB expression, ALT was detectable in five samples as the 
sole TMM and in six samples in association with telomerase. Seventeen 
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samples only expressed TA and in six cases no known TMM was 
appreciable. Results of TRF length distribution were available in 32 
cases, and a concordance between APB and TRF data in defining the 
ALT phenotype was found in 26/32 cases (81%). The study provides the 
first evidence of the presence of ALT in WT, and indicates that in a small 
but defined fraction of cases (about 15%) ALT is the only TMM that 
supports the development of WT. 
INTRODUCTION 
One of the hallmarks of cancer is a limitless proliferative capacity, which 
is strictly associated with the ability to maintain telomeres. Such an 
ability can be achieved through the activation of telomere maintenance 
mechanisms (TMMs). In 1994, Kim et al. made the landmark 
observation that telomerase activity (TA) is present in 85–90% of human 
cancers, whereas it is absent in most normal tissues. A minority of 
human cancers, ranging from 10 to 15%, is telomerase negative, and a 
fraction of them maintain telomeres through one or more mechanisms 
defined as alternative lengthening of telomeres (ALT). Several lines of 
evidence indicate that ALT involves a recombination-based mechanism 
(Dunham et al., 2000), and characteristics of ALT cells include long and 
heterogeneous telomeres and subnuclear structures, termed ALT-
associated promyelocytic leukemia (PML) bodies (APBs). These 
structures contain telomeric DNA, telomere-specific binding proteins 
TRF1 and TRF2, and proteins involved in DNA replication and 
recombination (Yeager et al., 1999). The prevalence of the ALT 
mechanism in human cancers is still largely undetermined, since most of 
the studies carried out so far investigated only telomerase expression. 
Available data indicate that ALT is more frequently present in tumors of 
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mesenchymal and neuroepithelial origin than in tumors of epithelial 
origin, probably due to a stronger telomerase repression in normal 
mesenchymal and neuroepithelial cells than in epithelial tissues 
(Henson et al., 2002). 
Wilms tumor (WT) or nephroblastoma is a pediatric malignancy of the 
kidney, and one of the most common solid cancers of childhood. WT is 
typically composed of a combination of epithelial, mesenchymal, and/or 
blastemal cells (Beckwith, 1983). Telomerase expression was 
investigated in WT; and, in different studies, high expression levels of 
the enzyme catalytic subunit TERT, or the telomerase RNA component 
TERC, were proposed as adverse prognostic factors (Dome et al., 1999, 
2005; Wittmann et al., 2008). Furthermore, in the two studies on the 
expression of the enzyme activity, most of the WT samples investigated 
were TA-positive (Dome et al., 1999, 2005). Conversely, no information 
is currently available on the presence of ALT in WT. 
In the present study, aimed at investigating the presence of ALT as the 
sole TMM or in association with TA, 34 WT samples were studied to 
provide a more complete description of the mechanisms involved in 
telomere maintenance in this disease. 
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MATERIALS AND METHODS 
Study Population 
Thirty-four WT samples from 30 patients treated at the Fondazione 
IRCCS – Istituto Nazionale Tumori (INT) of Milan from 2002 to 2008 
were investigated for TMM. The specimens were consecutive with 
respect to the availability of frozen tissue (containing at least 80% of 
tumor ells as assessed by hematoxylin and eosin) obtained immediately 
after surgical resection and stored in the INT Tissue Bank and of 
adequate clinico-pathologic and follow-up information. In two patients 
with bilateral presentation and in two who suffered from tumor relapse, 
both lesions were available for analysis. The clinicopathologic features 
of patients and tumors are reported in Table 1. Among the present 
series of 30 patients, 20 were untreated and 10 had undergone 
preoperative chemotherapy. Patients were treated according to the 
Associazione Italiana Ematologia Oncologia (AIEOP) protocol. Overall, 
four patients suffered from tumor relapse whereas the remaining 26 
patients were relapse-free at a median follow-up time of 46 months 
(range 9–76). The study was approved by the Ethics Committee of INT, 
and written informed consent to donate to the Institute the leftover tissue 
after diagnostic procedures was obtained from all patients’ parents or 
legal guardians. 
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Molecular Studies 
Tumor tissue was sampled by a pathologist at the time of surgery and 
flash frozen. A fragment of about 100 mg was cut from each lesion and 
further subdivided for APB detection and DNA, RNA, and protein 
extractions. A frozen section of each sample was stained with 
hematoxylin and eosin to check for the presence of tumor cells. 
Detection of ALT-Associated Promyelocytic Leukemia Nuclear 
Bodies 
APBs were assayed on frozen tissue sections by combined PML 
immunofluorescence and telomere fluorescence in situ hybridization 
(FISH), as previously described (Henson et al., 2005). Images were 
captured on a Nikon Eclipse E600 fluorescence microscope using ACT-
1 (Nikon, Tokyo, Japan) image analysis software and processed using 
Adobe Photoshop Image Reader 7.0 software. APB status was 
determined according to previously defined criteria (Henson et al., 
2005). The presence of an APB was defined by the localization of a 
telomeric DNA focus within a nuclear PML body. Sections were scored 
as APB+ if they contained APB in >0.5% of tumor cells, and a tumor was 
considered ALT+ when at least one section was APB+. To avoid false 
positives, an APB was considered to be present only when the telomeric 
DNA fluorescence within a PML body was more intense than that of 
telomeres, and a cell was not considered to contain APB if more than 
25% of the co-localized foci occurred outside of the nucleus. To avoid 
false negatives, at least 2,000 tumor nuclei were examined, and the 
assay was repeated in the presence of negative results. Tumor sample 
from an ALT+ (U2OS) cell line was used as positive control for the APB 
assay. 
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TABLE 1. Clinicopathological Data and Telomere Maintenance Mechanisms 
(TMMs) in the Investigated Series of Wilms Tumors.
      TMM 
Sample 
Gende
r 
Age 
(months
) 
Stage 
Pretreate
ment 
Type TA hTERT ALT TRF 
110 TR F 37 3 NO BES + + - - 
111 TL
a 
F 13 3 NO BES-DA + + - - 
112 TR M 44 3 NO B + + - - 
113 TR
a 
M 10 2 YES 
BES - - + - 
113 rel BES - + + - 
121 TR F 43 1 NO BES + + - - 
125 TL F 24 2 NO BES + + + + 
127 TL
a 
F 41 5 YES 
BES - + + + 
127 rel N - + + Ne 
128 TL F 74 2 NO E - - - - 
139 TL F 52 1 NO B + + + - 
146 TL F 30 1 YES BES - - - - 
154 TL M 57 2 YES BES + + - - 
159 TR F 53 2 NO S-DA + + - - 
161 TR 
M 14 5 YES 
BES + + + + 
161 TL BES + + + + 
163 TL M 44 1 NO E + + - - 
176 TR F 13 2 NO BES + + - - 
179 TL M 15 1 NO BES - - - + 
187 TR M 13 1 YES BES - - - - 
189 T F 5 1 NO BES + + + + 
195 TL F 16 1 NO BES + + - - 
196 TL M 23 1 NO BES + + - - 
198 TR M 4 1 NO BE + + + - 
201 TR F 64 3 NO BES + + - - 
211 TL
a 
F 33 3 YES BES - + - - 
256 TR F 20 1 NO B + + - - 
258 TL F 63 3 NO B + + - - 
267 TL F 6 1 NO B - + + + 
275 TL F 44 2 NO S + + - - 
282 T F 34 1 YES BES + + - Ne 
292 TR 
F 16 5 YES 
SE - - - + 
292 TL SE + + - - 
320 TR M 11 5 YES SE + + - - 
T: tumor, L: left side, R: right side, Rel: relapse; F: female, M: male, B: blastemal, E: epithelial, S: 
stromal, DA: diffuse anaplasia, N: necrosis; TMM: telomere maintenance mechanism, TA: 
telomerase activity, TERT: TERT transcript, APB: alternative lengthening of telomeres assessed 
on the presence of APB (ALT-associated promyelocytic leukemia nuclear bodies), TRF: 
alternative lengthening of telomeres assessed on the basis of terminal restriction fragment, Ne: 
not evaluable. a: Relapsed patient. 
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Telomere Length Analysis 
Total DNA was isolated using QuicKpicK genomic DNA kit (BioNobile, 
Medi Diagnostici, Milan, Italy) and telomere length was assessed by 
pulsed-field gel electrophoresis as previously described (Villa et al., 
2000). Autoradiographs were scanned (ScanJet IIcx/T; Hewlett Packard, 
Milan, Italy) and digitalized by Image Quant (Molecular Dynamics, 
Sunnyvale, CA). Each gel was standardized by inclusion of DNA from 
GM847 (ALT+) and HeLa (TA+) cell lines. ALT status was determined 
by calculating whether the mean, variance, and semi-interquartile range 
of the terminal restriction fragment (TRF) length distribution were greater 
than 16 kb, 1,000 kb2, and 4 kb, respectively. Tumors were classified as 
ALTþ when 2/3 or 3/3 of these criteria were met for unimodal or bimodal 
TRF length distributions, respectively. Statistical analysis of TRF length 
distributions was performed using Telometric software (Grant et al., 
2001). 
Telomerase Activity 
TA was measured on 0.6 and 6 µg of protein by the telomeric repeat 
amplification protocol (TRAP) (Kim et al., 1994) using the TRAPeze kit 
(Intergen, Oxford, UK). A tumor was scored as TA+ when positive TRAP 
results were obtained for at least one protein concentration. In the case 
of tumors negative at both protein concentrations, the TRAP assay was 
repeated to avoid false negatives. The TA+ cell line HeLa was used as 
positive control for the TRAP assay. Each experiment always included 
one heat inactivated sample to exclude contaminations and avoid false 
positive results. 
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RNA Extraction and Quantitative Real-Time Reverse Transcription 
(RT)-PCR Analysis of TERT 
Total cellular RNA was extracted from frozen samples with the TRIzol 
reagent (Life Technologies, Gaithersburg, MD). Total RNA (1 µg) from 
each sample was reverse-transcribed by random priming using the high 
capacity cDNA Archive kit (Applied Biosystems, Foster City, CA). TERT 
expression was assessed by quantitative real-time RT-PCR using 
TaqMan gene expression assay (Assay ID: Hs00972656_m1, Applied 
Biosystems), and the b-2-microglobulin (b2M) housekeeping gene was 
amplified as internal control (Assay ID: Hs 99999907_m1, Applied 
Biosystems). Amplifications were run on the 7900HT Fast Real-Time 
PCR System (Applied Biosystems), and data were analyzed by 
Sequence Detector System 2.2.2 software (Applied Biosystems) using 
the comparative Ct method for relative quantification of expression 
levels. The cDNA obtained from TA+ Hela cell line was used as positive 
control. 
Data Analysis
TMM measurements were performed by personnel blinded to patient 
data and clinical outcome (LV, RM), whereas clinical data were collected 
by personnel blinded to TMM results (FS, MT). The association between 
ALT and TA, as well as between ALT or TA and clinicopathologic 
features was assessed by the chi square test, adjusted for continuity 
when appropriate, or by Fisher’s exact test. SAS software (SAS 
Institutes, Inc., Cary, NC) was used to perform statistical calculations, 
and a two-sided P value <0.05 was considered statistically significant. 
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RESULTS 
Thirty-four WT samples obtained from 30 patients were characterized for 
TMMs. At least one TMM was detectable in 28/34 WTs (82%). Eleven of 
34 (32%) cases were classified as ALT+ on the basis of APBs being 
present in at least 0.5% of 2,000 tumor cells (Fig. 1A). Among the ALT+ 
samples, APBs were detected in a variable, but always limited, 
percentage of cells, ranging from 0.5% to 2.0%. At least two separate 
sections were examined for APBs, and the results revealed no 
intratumor heterogeneity for ALT (data not shown). In 32 lesions, results 
of TRF analyses were also available (Fig. 1B).  
Telomere length distribution of ALT+ samples are expected to be 
heterogeneous (range, <3 to >50 kb), whereas TA+ tumors usually 
display a more homogeneous distribution and a shorter average length 
of telomeres. Qualitative concordance between APB and TRF results in 
defining the ALT phenotype was found in 26/32 cases (81%). Twenty-
three of 34 (68%) WT specimens were classified as TA+ based on 
positive TRAP results on at least one protein concentration (Fig. 2).  
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Figure 1. ALT assays in Wilms tumors. A: APB assay: combined PML 
immunofluorescence and telomere FISH in a frozen section of ABP1 Wilms 
tumor. Telomere FISH was done using a Cy3-conjugated telomeric peptide 
nucleic acid probe (red stain). Indirect immunofluorescence was used for the 
PML protein (FITC label, green stain). Nuclei were counterstained with 40,6-
diamidino-2-phenylindole (DAPI) (blue stain). The foci of telomeric DNA that 
co-localize with PML represent APB. B: TRF southern blot analysis. Telomere 
length distribution of a representative series of Wilms’ tumors. The lengths of 
telomeres in ALT1 cells typically range from <3 to >50 kb. ALTcells typically 
have a more homogeneous distribution of telomere length and a shorter 
average length than ALT1 cells. 
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Figure 2. A representative TRAP experiment showing telomerase activity in 
Wilms tumor. The presence (1) or absence (2) of telomerase activity (TA) is 
reported for each sample using 0.6 and 6 µg of protein. The location of the 
internal amplification standard (ITAS) is reported. Positive control (TSR8) and 
negative control (heat inactivated sample, HI) as well as blank control (B) are 
shown. 
Expression of the catalytic component of telomerase TERT was found in 
all TA+ specimens and in 5/11 of TA- cases. Overall, based on the 
presence of APBs, five cases expressed ALT as the sole TMM 
(ALT+/TA-) with a mean percentage of APB+ cells of 1.1% (range, 0.5–
2.0), and six cases concomitantly expressed both TMM (ALT+/TA+) with 
a mean percentage of APB positive cells of 0.9% (range, 0.65-1.09). 
Seventeen samples only presented telomerase activation and six did not 
express any known TMM. 
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In four patients, more than one lesion was available for investigation. In 
the two cases in which both primary tumor and relapse were studied, the 
TMM phenotype was concordant (Table 1, samples 113 and 127). In two 
cases with bilateral disease presentation, a difference in TMM status 
was found in one case (Table 1, sample 292), in which the right and left 
tumors were ALT-/TA- and ALT-/TA+, respectively, while in the other 
case (Table 1, sample 161) both lesions were ALT+/TA+. TMM results 
as a function of patient clinicopathological data are summarized in Table 
1. TA and ALT (as defined by APB expression) were both unrelated to 
gender, age (namely older or younger than 24 months at diagnosis), and 
stage (1–5). Conversely, the presence of TA was more frequently 
observed in tumors from untreated patients compared to samples 
obtained from patients who underwent preoperative chemotherapy (P = 
0.042). The presence of APB proved to be unrelated to previous 
treatment. The small number of tumor relapses (four cases: one case 
TA+/ALT-, one case TA-/ALT-, two cases TA-/ALT+) did not allow the 
analysis of the clinical outcome as a function of TMM. 
DISCUSSION 
Telomere biology of pediatric tumors has been an object of investigation 
in recent years for the possible prognostic and therapeutic implications 
(Shalaby et al., 2010). Telomerase is expressed in most pediatric 
embryonal tumors and leukemia, whereas it is less consistently 
expressed in sarcomas and brain tumors. In general, a high level of 
telomerase expression correlates with aggressive disease and adverse 
patient outcome (for a review, see Tabori and Dome, Cancer 
Investigation, 2007). Among pediatric cancers, ALT presence has been 
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described in a significant percentage of osteosarcomas (Ulaner et al., 
2003; Sanders et al., 2004; Henson et al., 2005) and in a limited fraction 
of neuroblastoma (Henson and Reddel, 2010). Thus far, only a few 
studies have investigated the mechanisms by which telomeres are 
maintained in WT, and they focused exclusively on TA or on the 
expression levels of TERT and TERC, in the search for new prognostic 
biomarkers. TA, as determined by the TRAP assay (which provides a 
functional readout of the protein), has been investigated in two studies. 
The enzyme’s activity was detected in 58/72 (80%) and 157/164 (96%) 
cases, respectively, but without, any predictivity for relapse (Dome et al., 
1999, 2005). In the same studies, the expression levels of TERT mRNA 
and TERC was evaluated, and detectable levels were found in 97–99% 
and 100% of samples, respectively (Dome et al.,1999, 2005). Although 
the first study showed that TERT expression levels was an independent 
predictor of recurrence (Dome et al., 1999), the second study, involving 
a larger cohort of patients, revealed that levels of TERC expression was 
an even stronger predictive factor (Dome et al., 2005). In a different 
study, among 40 markers proposed for the classification and/or 
prediction of outcome in WT, which were investigated in 102 WTs and 
validated in an independent set of 74 WT cases, TERT turned out to be 
a potentially relevant marker of relapse and death (Wittmann et al., 
2008). To the best of our knowledge, WT has never been investigated 
for presence of the ALT mechanism. Different published data showing a 
higher frequency of ALT+ cases in tumors of mesenchymal and 
neuroepithelial origin (Henson et al., 2002), together with the pattern of 
gene expression in WT (which mimics the earliest committed stage in 
the metanephric mesenchymal-epithelial transition [Li et al., 2002]), 
prompted us to analyze the presence of ALT and, for comparative 
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purposes, TA in WT. In the study, we took advantage of a mono-
institutional series of WTs, which can be reasonably assumed to be 
uniform in terms of tumor specimen collection and processing, in order 
to avoid any possible variability in the results due to different sample 
handlings. 
Interestingly, 32% (11/34) of investigated WTs showed activation of the 
ALT mechanism. In five cases ALT was the sole mechanism responsible 
for telomere maintenance in the tumor. This finding could be clinically 
relevant as telomerase inhibitors come into use in clinical trials, since 
not all WTs would be susceptible to such therapies.
As regards telomerase, the enzyme activation was found to be present 
in 23 out of 34 studied samples. The frequency of tumors positive in the 
TRAP assay we detected in our case series (68%) was somewhat lower 
than that previously reported (80–96%) (Dome et al., 1999, 2005). Such 
a lower incidence may be due to methodologic differences or to the 
timing of nephrectomy, i.e., preoperative chemotherapy, that was 
administered approximately to one-third of our patients, since a trend in 
favor of a more frequent telomerase activation was observed in 
untreated compared to treated tumors. 
A concomitant presence of the two TMMs was observed in six WT 
samples (18%). Although a simultaneous activation of TA and ALT has 
already been observed in other neoplasms, such as osteosarcoma 
(Ulaner et al., 2003), liposarcoma (Montgomery et al., 2004; Johnson et 
al., 2005; Costa et al., 2006), glioblastoma multiforme (Hakin-Smith et 
al., 2003), and diffuse malignant peritoneal mesothelioma (Villa et al., 
2008), it is yet not known whether both TMMs coexist in the same 
neoplastic cell or whether the two distinct mechanisms represent 
different ALT+ and TA+ tumor subpopulations. Evidence obtained in 
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ALT cells engineered to express hTERT suggests that the two TMMs 
can function concurrently in most (Cerone et al., 2001; Grobelny et al., 
2001; Perrem et al., 2001; Stewart et al., 2001) but not all models 
investigated (Ford et al., 2001). 
The assay we used to investigate TERT mRNA measures the total 
amount of transcripts and does not discriminate among the alternatively 
spliced isoforms. The evidence that some cases, which are TA- in the 
TRAP assay, express the TERT transcript confirms that the presence of 
the TERT mRNA is necessary but not sufficient to activate the enzyme. 
Furthermore, we cannot exclude the presence of a mutated TERT gene 
or imbalances in the different transcripts, which have been 
demonstrated to affect TA in other tumor types (Villa et al., 2001; 
Brambilla et al., 2004; Zaffaroni et al., 2005; Villa et al., 2008). 
Although telomerase and ALT appear equivalent in their ability to 
support immortalization, their contribution to tumor progression may 
differ. Our preliminary evidence that one locally relapsing tumor (sample 
113) showed ALT as the sole TMM would indicate that ALT+ WTs may 
nevertheless be highly malignant, as previously observed in other tumor 
types (Hakin-Smith et al, 2003; Ulaner et al., 2003; Costa et al., 2006). 
Six cases (18%), despite being informative in the different assays used 
in the study, seemed to possess no known TMM. Although we cannot 
exclude that this results could be due to the sensitivity of our assays, the 
existence of ALT-/TA- lesions has already been observed in other tumor 
types (Hakin-Smith et al., 2003; Ulaner et al., 2003; Costa et al., 2006), 
suggesting the presence of a not yet identified TMM in these lesions, or, 
alternatively, that the acquisition of a constitutively active TMM is not a 
stringent requirement for this subset of tumors, in agreement with 
experimental data that showed that TMM activation is not always 
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required for malignant transformation of normal human cells (Seger et 
al., 2002). A further possibility is that, based on the presence of APBs, 
the ALT phenotype is underestimated, since, at least in liposarcomas, 
some tumors activate the ALT mechanism in the absence of APBs 
(Jeyapalan et al., 2008). In conclusion, this study provides the first 
evidence of the presence of ALT in approximately one-third of WTs, 
indicating that in a small but significant fraction of cases (about 15%) 
ALT is the only TMM that supports WT development. 
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Abstract 
The study aimed at investigating the prevalence of the two known 
telomere maintenance mechanisms (TMMs), telomerase activity (TA) 
and alternative lengthening of telomeres (ALT), and assessing their 
prognostic relevance in malignant peripheral nerve sheath tumors 
(MPNST). In 57 specimens obtained from 49 patients with MPNST (35 
sporadic and 14 neurofibromatosis type 1-related), TA was determined 
using the telomeric repeat amplification protocol and ALT was detected 
by assaying both ALT-associated promyelocytic leukemia bodies (APB) 
and terminal restriction fragment (TRF) length distribution. TA or ALT (as 
detected by the presence of APB) alone was found in 24.6% or 26.3% of 
the lesions, respectively, whereas 6 cases (10.5%) were TA+/ALT+. A 
concordance between APB and TRF results in defining the ALT status 
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was observed in 44 of 57 cases (77.2%; P<0.0001). TA was found to be 
more frequently expressed in samples from patients with 
neurofibromatosis type 1-related MPNST than in those with sporadic 
disease (60% vs 29.4%, P=0.087). In the overall series, TA proved to be 
prognostic for 5-year disease-specific death (Hazard Ratio, 3.78; 95% 
CI, 1.60-8.95; P=0.002). These findings held true even when adjusted 
for the concomitant presence of neurofibromatosis type 1 syndrome 
(Hazard Ratio, 4.22; 95% CI, 1.804-9.874; P=0.001) and margin status 
after surgery (Hazard Ratio, 5.78; 95% CI, 2.19-15.26; p<0.001). 
Conversely, ALT failed to significantly affect clinical outcome of MPNST 
patients either using APB expression (Hazard Ratio,1.25; 95% CI 0.54-
2.89; P=0.605) or TRF distribution (Hazard Ratio 0.57; 95% CI 0.17-
1.96; P=0.375) as the detection approach. Our results indicate for the 
first time that both known TMMs, TA and ALT, are present in MPNST 
and differentially affect patient prognosis. 
Keywords: telomere maintenance mechanisms, telomerase, alternative 
lengthening of telomeres, malignant peripheral nerve sheath tumors, 
schwannoma.  
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Introduction 
Peripheral nerve sheath tumors constitute a group of relatively rare soft 
tissue neoplasms which includes benign lesions deriving from specific 
neural tissues (neurofibromas and schwannomas) and malignant 
peripheral nerve sheath tumour (MPNSTs) that most commonly involve 
major nerve trunks (1). MPNSTs are highly aggressive malignancies that 
account for 3-10% of all soft tissue sarcomas (2). Approximately 50-60% 
of MPNSTs occur in the setting of neurofibromatosis type 1 (NF1), a 
hereditary tumor syndrome, and are the leading cause of NF1-related 
mortality (3,4). The remainder of MPNSTs develop sporadically. In 
patients with NF1, MPNST usually arise in the presence of a 
neurofibroma or, very rarely, a schwannoma (5). 
Complete surgical excision is the mainstay of MPNST therapy and 
represents the primary curative modality. Adjuvant chemotherapy and 
radiation therapy are also often used. However, despite the aggressive 
treatment, local recurrence and metastases are common, leading to a 
poor prognosis for MPNST patients, with 5-year survival rates ranging 
from 20-50%. These finding strongly indicate an urgent need for 
improved therapeutic approaches able to significantly impact on the 
disease outcome (6). 
MPNST pathogenesis is poorly understood due mainly to its 
complex histopathology. A number of molecular and genetic alterations 
have been found in relation to these tumors (7-10). However, there is no 
defined molecular signature for MPNST development, although recent 
work in the field of MPNST molecular pathobiology has identified several 
altered receptor tyrosine kinase-mediated intracellular signal 
transduction cascades, posing the possibility of utilizing personalized, 
targeted therapeutics for the disease (11).  
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The activation of a telomere maintenance mechanism (TMM) is 
essential for tumor cells to counteract the normal limit on cell 
proliferation resulting from progressive telomere shortening that normally 
accompanies each round of cell division (12). Indeed, limitless 
proliferative potential is a hallmark of cancer cells. There are two known 
TMMs: telomerase (13) and alternative lengthening of telomeres (ALT) 
(14). Telomerase is a ribonucleoprotein complex containing an RNA 
subunit, hTR, that provides the template for the synthesis of telomeric 
DNA by the catalytic subunit, hTERT (15). Approximately 85-90% of all 
tumors express telomerase (16), whereas most of the remaining tumors, 
mainly those of mesenchymal and neuroepithelial origin (17-24), rely on 
ALT to maintain their telomeres.  
Although the molecular details of ALT are incompletely 
understood, previous studies have shown that it is consistent with a 
recombination-dependent DNA replication mechanism (14). 
Characteristics of ALT cells include an extremely heterogeneous 
telomere length distribution, ranging from very short to more than 50 kb, 
and the presence of subnuclear structures termed ALT-associated 
promyelocytic leukemia (PML) bodies (APBs) (14). PML bodies are 
normal nuclear domains of unknown function that contain the PML 
protein. In ALT cells, a subset of the PML bodies contains telomeric 
chromatin (telomeric DNA and the telomere binding proteins TRF-1, 
TRF-2, TIN2 and RAP1) as well as other proteins involved in DNA 
replication, recombination and repair (14). Another specific feature of 
ALT mechanisms is the presence of C-circles (self-priming circular 
telomeric DNA), which may represent molecular intermediates of the 
ALT mechanism and whose specificity for assessing ALT activity in 
biological samples has recently been demonstrated (25).
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Because the presence of an active TMM is an almost universal 
feature of cancer, and normal cells do not have sufficient levels of TMM 
activity to counteract telomere shortening, in recent years TMMs have 
been suggested as attractive new targets for anti-cancer therapies 
(26,27), particularly for those tumor types, such as MPNST, that are 
refractory to conventional therapeutic interventions. In this context, it is 
important to know whether individual MPNSTs use telomerase or ALT to 
maintain their telomeres. In a previously published study, telomerase 
activity was found to be present in about 60% of MPNST samples 
derived from NF1-affected patients (28). However, no information is 
currently available concerning the presence of ALT in MPNSTs. Taking 
advantage of a relatively large mono-institutional series of MPNST 
patients with long follow-up, in this study we propose to investigate the 
prevalence of telomerase activity (TA) and ALT, and whether they 
contribute to clinical progression in this disease.
Materials and methods
Study Population. A total of 57 lesions taken from 49 adult patients 
(median age 40 years, range 18-90) treated with curative intent at the 
Fondazione IRCCS Istituto Nazionale dei Tumori of Milan (INT) from 
November 1990 to January 2007 were available for analysis. Fourteen 
patients had NF1 with an associated MPNST, and 35 were classified as 
having sporadic tumors because they had no clinical signs or family 
history of NF1. The specimens, stored in the Institutional Tissue Bank, 
were consecutive with respect to the availability of frozen tissue for TMM 
studies and adequate clinicopathologic and follow-up information. Six 
patients developed recurrence and/or metastasis during the follow-up 
period, and the corresponding 8 lesions were collected and included in 
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the analysis. Patient and tumor characteristics are summarized in Table 
1. The median follow-up of the entire group, was 46 months (range: 3 to 
240). During the follow-up period, 23 patients died for cancer-related 
causes. Fourteen benign schwannoma lesions, obtained from 14 
patients who underwent surgery, were included in our research for 
comparative purposes. The study was approved by the Institutional 
Review Board of INT, and each patient provided written informed 
consent to donate to the Institute the tissues left over after diagnostic 
procedures. 
Table 1. Patient and tumor characteristics
No. of patients 
Total 49 (100%) 
Gender: 
Female 20 (41.0%) 
Male 29 (59.0%) 
Syndrome: 
Sporadic 34 (69.4%) 
Site 
Trunk 17 (34.7%) 
Type of lesion at first presentation  
Primary 42 (85.7%) 
Recurrence 4 (8.2%) 
Metastasis 3 (6.1%) 
Size (cm) 
Grade (FNCLCC):  
1 5 (10.2%) 
2 14  (28.6%) 
3 23 (46.9%) 
Missing 7  (14.3%) 
Post-surgery treatment  
Surgery only 20 (40.8%) 
Chemotherapy 11 (22.4%) 
Radiotherapy 11 (22.4%) 
Chemotherapy + radiotherapy 5 (10.2%) 
Missing 2 (4.1%) 
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Molecular studies. Normal and tumor tissues were sampled by a 
pathologist at the time of surgery, flash-frozen in liquid nitrogen, and 
stored at -80 °C. Diagnosis and sampling adequacy w ere pathologically 
confirmed on H&E-stained slides. A fragment of 70 to 100 mg was cut 
from each lesion and further subdivided for APB detection, protein 
extraction for telomerase activity (TA) assay and DNA extraction for 
telomere length assessment and array-CGH. 
Detection of APB. Frozen sections were cut to 5 to 7 m thickness, 
fixed in 1:1 methanol/acetone, processed to detect APB by combined 
PML immunofluorescence and telomere fluorescence in situ 
hybridization (21), and independently scored by two observers. Images 
were captured on a Nikon Eclipse Ti  fluorescence microscope using 
Volocity 5.3  (Perkin-Elmer) image analysis. APB status was determined 
according to previously defined criteria (21). The presence of an APB 
was defined by the localization of a telomeric DNA focus within a nuclear 
PML body; sections were scored as APB positive if they contained APB 
in 0.5% of tumor cells; and a tumor was considered ALT+ when at least 
one section was APB positive. To avoid false positives, an APB was 
considered to be present only when the telomeric DNA fluorescence 
within a PML body was more intense than that of telomeres, and a cell 
was not considered to contain APB if >25% of the colocalized foci 
occurred outside the nucleus. To avoid false negatives, at least 2,000 
tumor nuclei were examined, and the assay was repeated in the 
presence of negative results. An ALT+ (U2OS) cell line was used as a 
positive control. In order to assess whether APB were present in tumor 
cells and not in admixed stromal cells, we simultaneously performed 
indirect immunofluorescence for NF1 protein on the frozen sections 
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using a commercial antibody (sc-67, Santa Cruz Biotechnology, Santa 
Cruz, CA). 
Telomerase activity detection assay. TA was measured on 0.6 and 6 
µg of protein by the telomeric repeat amplification protocol (TRAP) (29), 
with the TRAPeze kit (Intergen Company). A tumor was scored as TA+ 
when positive TRAP results were obtained for at least one protein 
concentration. In the case of tumors negative at both protein 
concentrations, the TRAP assay was repeated to avoid false negatives.  
Terminal restriction fragment (TRF) analysis. Total DNA was isolated 
isolated using QuicKpicK genomic DNA kit (BioNobile), digested with 
HinfI restriction enzyme (Promega) and further processed by pulsed-
field gel electrophoresis as previously described (30). ALT status was 
determined by calculating whether the mean, variance, and semi-
interquartile range of TRF length distribution were greater than 16 kb, 
1,000 kb2, and 4 kb, respectively. Tumors were classified as ALT+ when 
two of three or three of three of these criteria were met for unimodal or 
bimodal TRF length distributions, respectively. Statistical analysis of 
TRF length distributions was done with Telometric software (31).
Array CGH. The analysis was performed on genomic DNA derived from 
31 MPNST (16 NF1-related, 15 sporadic) lesions, using the Agilent’s 
Human Genome CGH Array 44K (Agilent Technologies). Total DNA was 
isolated with QuicKpicK genomic DNA kit (BioNobile). For each CGH 
hybridization, 1 g of genomic DNA from the experimental sample and 
suitable reference DNA (female XX or male XY, Promega) was digested 
with AluI and RsaI restriction enzyme (Promega). Labeling reactions 
were performed using Agilent Genomic DNA Enzymatic Labeling Kit 
according to the manufacturer's instructions with a modified dNTP pool 
containing Cy5-dUTP (for the experimental sample) or Cy3-dUTP (for 
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the reference). Labeled samples and references were subsequently 
filtered by using a Microcon YM-30 column (Millipore). Specific activity 
was calculated for each sample as a ratio between dyes pmol and g of 
DNA, then experimental and reference targets for each hybridization 
were pooled and mixed with human Cot-1 DNA (Invitrogen). The 
samples were loaded in an hybridization chamber, with a clean Gasket 
Slide and a Microarray Slide (Agilent Technologies). Then hybridization 
was carried out for 24 hours at 65 °C  in a rotatin g oven. The arrays 
were then disassembled and washed in specific buffers (Agilent 
Technologies) according to manufacturer’s instructions, then slides were 
dried and scanned using Agilent Scanner (Agilent Technologies). 
Microarray images were extracted and analyzed using Agilent Feature 
Extraction Software. Data from arrays were analyzed using Agilent CGH 
Analytic Software 3.4 (Agilent Technologies). 
Statistical analysis. The clinical end point of this study was disease-
specific survival, and the time of its occurrence was computed from the 
date of surgery to the time of death or censored at the date of the last 
recorded follow-up for living patients. Survival curves were estimated by 
means of the Kaplan-Meier product limit method (32), and the Cox 
proportional hazards model (33) was used to calculate hazard ratios 
(HR) and their 95% confidence interval (95% CI). Fisher’s and 2 exact 
tests were used to assess the relationship between TMM status and 
clinico-pathological features. All P values were two-sided, and values 
0.05 were considered statistically significant. The agreement between 
APB and TRF data was assessed by kappa statistics. 
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Results
Fifty-seven frozen tumor samples obtained from 49 patients with 
MPNST were assayed for the presence of TMM (Table 2). TA was 
detected by the TRAP assay (Fig. 1A), and tumors were defined as 
ALT+ on the basis of APB presence in at least 10 (0.5%) of 2,000 tumor 
cells (Fig. 1B). Thirty-five lesions (61.4%) expressed at least one TMM. 
Specifically, 14 lesions (24.6%) were TA+/ALT-, 15 (26.3%) were TA-
/ALT+, and 6 (10.5%) were defined as TA+/ALT+ due to the concomitant 
expression of APB and TA. A consistent fraction of tested samples 
(22/57, 38.6%) did not express any known TMM.  
In ALT-positive samples, APBs were observed in a variable but always 
limited fraction of cells, ranging from 0.5% to 5.7% (mean value, 1.29%). 
Specifically, the percentage of APB-positive cells ranged from 0.59 to 
5.7% (mean value, 1.4%) and from 0.5 to 2.15% (mean value, 0.99) in 
TA-/ALT+ and TA+/ALT+ group, respectively. For all 57 samples, results 
of TRF analysis (Fig. 1C) were also available and we found 
concordance between APB and TRF results in defining the ALT status in 
44 cases (77.2%; kappa= 0.437; 95% CI, 0.215-0.659; P<0.0001). 
Specifically, 8 lesions (14.0%) were defined as ALT+ and 36 (63.2%) 
were defined as ALT- with both detection methods, while the remaining 
13 lesions (22.8%) were defined as ALT+ on the basis of APB 
expression but did not show a TRF length distribution suggestive of ALT. 
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Table 2: Telomerase activity and ALT mechanisms in MPNST lesions. 
Case Lesion TA APB TRF length
1 NF1 1 R + - -
2 NF1 2A M + - -
2B M + + -
3 NF1 3A R + + -
3B R - - -
4 NF1 4A P + - -
4B R - + -
5 NF1 5A P - + -
5B R - - -
6 NF1 6 P + - -
7 NF1 7 P - - -
8 NF1 8 P + - -
9 NF1 9 P - + +
10 NF1 10 P + - -
11 NF1 11 P + - -
12 NF1 12 P + + -
13 NF1 13 P - - -
14 NF1 14 P - - -
15 NF1 15 P - + +
16 sporadic 16 P - - -
17 sporadic 17 P - + +
18 sporadic 
18A R + - -
18B R - + -
18C R - - -
18D R - - -
19 sporadic 19 R - + -
20 sporadic 20 P - - -
21 sporadic 21 M + + -
22 sporadic 22 P - + -
23 sporadic 23A P - - -
23B M - + +
24 sporadic 24 P + + -
25 sporadic 25 P - - -
26 sporadic 26 M + - -
27 sporadic 27 P - + +
28 sporadic 28 P - - -
29 sporadic 29 P - + +
30 sporadic 30 P + - -
31 sporadic 31 P - + -
32 sporadic 32 P - - -
33 sporadic 33 P - + -
34 sporadic 34 P + - -
35 sporadic 35 P + - -
36 sporadic 36 P + + +
37 sporadic 37 P - - -
38 sporadic 38 P - - -
39 sporadic 39 P + - -
40 sporadic 40 P - - -
41 sporadic 41 P - - -
42 sporadic 42 P - + +
43 sporadic 43 P - - -
44 sporadic 44 P - + -
45 sporadic 45 P - - -
46 sporadic 46 P + - -
47 sporadic 47 P - - -
48 sporadic 48 P - - -
49 sporadic 49 P - - -
NF1: Neurofibromatosis type 1, P: primary disease, R: recurrent locoregional tumor, M: 
metastatic lesion, TA: telomerase activity, APB: alternative lengthening of telomeres 
assessed on the presence of APB (ALT-associated promyelocytic leukaemia nuclear 
bodies), TRF: alternative lengthening of telomeres assessed on the basis of terminal 
restriction fragment length distribution. 
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Figure 1. (A) Two representative specimens of MPNST in which telomerase 
activity was detected by the TRAP assay using 0.6 and 6 µg of protein. The 
location of the internal amplification standard (ITAS) is indicated. (B) APB 
assay in MPNST: combined PML immunofluorescence and telomere 
fluorescence in situ hybridization in a frozen section of a representative ABP-
positive MPNST sample. Indirect immunofluorescence was used for the PML 
protein (FITC label, green stain); telomere FISH was done using a Cy3 
conjugated telomeric peptide nucleic acid probe (red stain); nuclei were 
counterstained with 4’,6-diamidino-2-phenylindole, DAPI (blue stain); the foci of 
telomeric DNA that colocalize with PML represent APBs (white arrows). (C). 
Terminal restriction fragment (TRF) profiles of four representative MPNST 
specimens. 
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The presence of ALT, as determined on the basis of APB presence, was 
unrelated to gender (P=0.966), age (P=0.201), tumor location (P=0.826), 
grade (P=0.999), size of the lesion (p=1.000) and NF1 syndrome (P= 
0.964). Such findings were also observed when ALT was determined on 
the basis of TRF analysis (data not shown). As regards TA, it did not 
prove to correlate with gender (P = 0.298), age (P=0.636), tumor 
location (P= 1.000), grade (P = 0.603) and size of the lesion (P=0.885). 
However, TA was found to be more frequently expressed in samples 
from patients with NF1-related MPNST than in those with sporadic 
disease (60.0 vs 29.4%, P= 0.087). 
As far as the 14 benign schwannoma lesions are concerned, none of 
them expressed TA whereas 2 lesions were scored as ALT+ on the 
basis of APBs (0.52% and 1.11% APB-positive cells), although they did 
not show a TRF distribution pattern consistent with ALT. 
Array CGH data, obtained in a subset of 31 MPNST samples, both 
sporadic and NF1-associated, exhibited significant DNA copy number 
changes, with variations in size, span and nature of the aberrations on 
the whole genome (data not shown). In particular, relevant to TMMs, we 
could detect a copy number gain of hTERT gene on chromosome 5 in 
20/31 (65%) samples, with a similar percentage in NF1-associated 
(69%) and sporadic (60%) MPNSTs (Fig. 2A). When considering the 
prevalence of hTERT aberration in relation to the TMM operating in the 
tumor, we found a slightly higher frequency of copy number gain of 
hTERT gene in TA+/ALT- tumors (7/10, 70%) that in TA-/ALT+ tumors 
(5/9, 56%).  In addition, aCGH results for NF1 gene on chromosome 
17q11 revealed no significative differences between NF1-associated 
and sporadic tumors with a copy number loss of NF1 gene in 9/16 (56%) 
of NF1 related tumors and in 8/15 (53%) sporadic lesions (Fig. 2B). 
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Figure 2. Copy number variation of hTERT gene (A) and NF1 gene (B) in a 
subset of 31 MPNSTs. Samples arising in the context of NF1 syndrome are 
highlighted in red.  
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Clinical outcome was analyzed on the overall series of 49 MPNST 
patients. After 5 years of follow-up, 22 patients had died of the disease, 
and only 1 additional patient died in the 5 to 10 years interval, which 
corresponds to survival estimates of 47% and 39%, respectively. From 
the survival analyses, we found a correlation between the degree of 
surgical excision and disease specific survival in univariable analysis 
(Margin status: positive (negative): HR 4.11, 95% CI 1.67-10.10, 
p=0.002) (Table S1).  
Conversely, age, presence of NF1 syndrome, location of the tumor, size, 
and grade did not show any statistically significant correlation with 
patients’ prognosis (Table S1). As far as the prognostic relevance of 
TMMs is concerned, for 6 patients who experienced progressive disease 
(recurrence or metastasis), and whose ALT/TA status changed during 
the course of the disease, the appearance of any TMM defined the final 
phenotype (e.g., if metachronous lesions were ALT+ and ALT-, the 
patient would be categorized as ALT+). At 5 years of follow-up, TA 
proved to be significantly associated with disease-specific mortality. 
Specifically, results obtained from univariable analysis showed that 
patients with TA+ tumors had a significantly lower probability of being 
alive than patients with TA− (Hazard Ratio [HR], 3.78; 95% CI 1.60-8.95; 
P = 0.002) (Fig.3A). Such findings held true also when adjusted for the 
presence of NF1 syndrome (HR, 4.22; 95% CI, 1.804-9.847; P = 0.001) 
and for the margin status after surgical excision (HR, 5.78; 95% CI, 
2.19-15.26; p<0.001) (Table S1). Conversely, ALT alone did not prove to 
be associated with disease-specific mortality either using APB 
expression (HR,1.25; 95% CI 0.54-2.89; P=0.605) (Fig. 3B) or TRF 
distribution analysis (HR, 0.57; 95% CI 0.17-1.96; P=0.375) to define 
ALT status. 
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Table S1 
Univariable analysis  
Category (reference) HR 95%CI p 
TA:  present (absent) 3.78 1.60-8.95 0.002 
APB: present (absent) 1.25 0.54-2.89 0.605 
TRF: present (absent) 0.57 0.17-1.96 0.375 
Age:  40 years (>40 years) 0.97 0.42-2.26 0.949 
Syndrome:  NF1 (sporadic) 0.96 0.40-2.63 0.956 
Tumor site:  trunk (extremity) 0.88 0.36-2.17 0.788
Tumor size:  >5cm (5cm) 5.75 0.77-43.11 0.089 
Margin status:  positive (negative) 4.11 1.67-10.10 0.002 
Tumor grade:  grade 2 (grade 1) 1.88 0.22-16.12 0.563 
                          grade 3 (grade 1) 3.47 0.45-26.77 0.233 
                          grade 3 (grade 1+2) 2.11 0.79-5.67 0.138 
Bivariable analysis adjusted for  margin status 
Category (reference) HR 95%CI p 
TA: present (absent)  5.78  2.19-15.26  <0.001  
APB: present (absent)  1.36  0.57-3.25  0.495  
TRF: present (absent)  0.63  0.20-2.02  0.436  
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Figure 3. Disease-specific survival as a function of TA (A) and ALT (B) in 
MPNST patients. 
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Discussion 
This is the first report of a comparative analysis of the expression and 
clinical relevance of the two currently known TMMs, ALT and TA, in a 
monoinstitutional series of MPNSTs, including both sporadic and NF1-
associated tumors. Overall, TA was detected in 35.1% of the lesions, 
although it was found to be more frequently expressed in samples from 
patients with NF1-associated MPNST than in those with sporadic 
disease (60.0 vs 29.4%). This observation is consistent with previous 
data from Mantripragada et al. (28), who recorded TA in 61% of MPNST 
samples derived from NF1-affected patients. The authors also showed 
that all TA+ lesions were high grade MPNSTs. Conversely, in our case 
series we were able to detect TA also in a low grade sporadic MPNST 
lesion (out of 5  grade 1 lesions tested). Through a genome–wide high 
resolution analysis of DNA copy number alterations in NF1-associated 
MPNSTs and benign tumors, the same research group (29) was able to 
reveal amplification of the hTERT gene in malignant tumors but not in 
benign lesions. Array CGH results we generated in a subset of 31 
MPNSTs showed that such an amplification was also present in 
sporadic MPNSTs, in a percentage of cases superimposable to that 
found in NF1-associated tumors (60% vs 69%). The similar genetic 
alterations we observed in sporadic and NF1 associated MPNST (as 
outlined in hTERT and NF1 gene) are not surprising. Indeed Brekke et 
al. (Brekke HR, Ribeiro FR, Kolberg M, Agesen TH, Lind GE, Eknaes M, 
Hall KS, Bjerkehagen B, van den Berg E, Teixeira MR, Mandahl N, 
Smeland S, Mertens F, Skotheim RI, Lothe RA. Genomic changes in 
chromosomes 10, 16, and X in malignant  peripheral nerve sheath 
tumors identify a high-risk patient group. J Clin Oncol. 2010 Mar 
20;28(9):1573-82) recently suggested that the genetic events leading to 
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MPNST are comparable in NF-related and sporadic tumors. It is 
noteworthy that the observed amplification of hTERT gene is in 
agreement with gene up-regulation in MPNSTs, as previously detected 
by real-time RT-PCR (34). No clear correlation between hTERT copy 
number gain and TA was evident since such a genomic alteration was 
also found in half ALT+ lesions as well as in a high percentage of TA-
/ALT- tumors. 
ALT was found in 36.8% of cases when APB expression was used as 
the detection approach, and the percentage of ALT+ tumors decreased 
to 14% when the ALT phenotype was determined on the basis of TRF 
length distribution. The incomplete overlapping of the results obtained 
with the two methods is not surprising. In fact, while the APB assay 
allows the analysis of individual tumor cells, the TRF pattern could be 
misleading due to the admixture of normal and tumor cells present in the 
specimens. However, based on available data, the concordance rate 
between the two assays seem to be dependent on the tumor type. 
Specifically, the 77.2% concordance rate between the two approaches 
in defining MPNST specimens as ALT+ or ALT- is superimposable to 
that (77.6%) we previously observed in a series of 85 liposarcoma 
specimens that were comparatively assayed for ALT with the two 
detection methods (35). Conversely, Henson et al. (21) reported a 
complete agreement in the results of the two assays in glioblastoma 
multiforme.  
In six patients, more than one lesion was available for TMM 
investigation. In three cases in which both primary tumor and 
subsequent lesions were studied, the TA status was concordant 
(Table2, case 2, 5 and 23), while for the other 3 patients TA status 
changed during the course of the disease (Table2, case 3, 4 and 18 ). 
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As far as ALT status is concerned, the presence of APB varied in all the 
patients with metachronous lesions, while TRF phenotype remained 
stable in 5 out of 6 patients (Table2).  
The observation that MPNSTs utilize either TA or ALT to maintain their 
telomeres suggest that subsets of tumors can undergo different 
pathways of tumorigenesis. In this context, we previously demonstrated 
that distinct gene expression signatures can distinguish tumors and cell 
lines that are TA+ from those that are ALT+ (36).  
As already reported for other tumor types (17,18,20,22,23), in a few 
MPNSTs we found a concomitant expression of TA and ALT confirming 
the possibility that the two TMMs can coexist in the same lesion. 
However, at present it is unclear whether TA and ALT can be present 
within the same tumor cell or whether a given tumor lesion may contain 
distinct ALT+ and TA+ subpopulations. On the other hand, we found that 
a significant percentage of MPNSTs (40%) possessed no apparent 
TMM despite being informative for the different assays, suggesting that 
the presence of a constitutively active TMM is not a stringent 
requirement for a subset of MPNSTs, or, alternatively, that these tumors 
use a mechanism that has not yet been identified. Moreover, such a lack 
of any known TMM, previously observed also in subsets of other tumor 
types (17, 18, 22, 23), is in accord with experimental data suggesting 
that TMM acquisition is not always required for malignant transformation 
of normal human cells (37). However, the possibility that the lack of 
TMM expression observed in a high percentage of the tested MPNSTs 
may be related, at least in part, to the sensitivity of the assays used 
cannot be excluded.  
The activation of a TMM is able to overcome replicative 
senescence induced by cell division-associated telomere attrition. In a 
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previous study, carried out in a series of mesenchymal tumors, including 
16 MPNSTs, and aimed to understand the contribution of senescence 
signaling to the biology of these tumors, we used a senescence scoring 
approach based on expression profiling of well-defined senescence 
markers as a means to evaluate latent senescence pathways. 
Specifically, a DNA damage associated signature (DAS) and a modified 
secretory senescence signature (mSS) were used. Results we obtained 
indicated that, at an individual tumor level, DAS and mSS scores were 
not correlated, suggesting that senescence phenotypes may be 
differentially activate during transformation (38).  
Concerning benign schwannomas, we did not found evidence of 
TA in any of the 14 samples tested, in agreement with previous data by 
Chen et al. (39) who reported as TA- all 30 schwannoma samples 
considered in their study. The authors also characterized the specimens 
in term of TRF length distribution analysis and could identify 4 lesions 
having elongated telomeres: 3 of them showed an aggressive 
clinicopathological behaviour. In addition, one patient died of the 
disease, and one experienced a clinical recurrence. In our case series, 
no schwannoma lesion could be defined as ALT+ on the basis of TRF 
results, but two lesions were defined as ALT+ based on APB 
expression. Unfortunately, since no follow-up data are available for 
these patients, we cannot estimate the possible relevance of ALT 
phenotype on the clinical outcome.  
As far as the prognostic relevance of TMMs in MPNST is 
concerned, TA proved to be prognostic for disease-specific survival. 
Specifically, patients with TA+ tumors had a significantly lower 
probability of being alive at 5 years after surgery than patients with TA- 
tumors. In addition, TA proved to be a strong prognostic discriminant of 
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increased mortality even when adjusted for the concomitant presence of 
NF1 syndrome and for margin status after surgical excision. Results 
available in the literature indicate an association between telomerase 
activity/expression and poor prognosis in different tumor types, including 
breast, non-small cell lung cancer, gastric and colorectal cancer, and 
neuroblastoma (40), although not all the published studies confirmed 
such an association.  
In our series of MPNST patients, ALT failed to significantly affect 
clinical outcome, independently of the detection method used. Based on 
available information, the association of ALT with patient prognosis 
seems to be disease related. In glioblastoma multiforme, a better 
survival for patients with a ALT+ tumor was consistently observed in 
three studies in which ALT phenotipe was detected by TRF analysis or 
the presence of APB (17, 21, 24). On the opposite, in liposarcoma 
patients, we found that ALT proved to be a stronger prognostic 
discriminant of increased mortality than TA in both univariable and 
multivariable analysis (22). Again, we reported a negligible role for ALT 
in the prognosis of patients with diffuse malignant peritoneal 
mesothelioma (23). A possible tentative explanation for the different 
outcomes may be that ALT activation results from different sets of 
tumor-specific genetic changes that are correlated with a better or worse 
prognosis as a function of the tumor type. 
The lack of reliable therapeutic options, other than complete 
surgery, for MPNST together with our observation that this tumor may 
utilize either TA or ALT to maintain telomeres, suggests the opportunity 
to consider TMMs as new therapeutic targets for the disease. In this 
context, the characterization of the TMM operating in individual tumors 
could allow the identification of patients suitable for treatment with anti-
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telomerase drugs which are currently used in the clinical practice (41). In 
addition, preclinical evidence indicating that ALT+ tumor models are 
sensitive to compounds that induce telomere dysfunction by binding to 
G-quadruplex structures in telomeric DNA and inhibit tumor growth 
through a mechanism largely independent of the presence of active 
telomerase (27), would suggest the possibility, in the near future, to treat 
ALT+ MPNST patients with these compounds as soon as they reach the 
clinical setting.  
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Supplementary table 1 
Characteristics of peritoneal mesothelioma specimens included for miRNA 
expression profiling.
subtype TA ALT 
MP10 Epithelial + - 
MP14 Epithelial - + 
MP18 Epithelial + - 
MP19 Epithelial + - 
MP2 Epithelial + - 
MP20 Epithelial + - 
MP21 Epithelial + + 
MP22 Epithelial + - 
MP25 Epithelial 
(deciduoid)
+ - 
MP27 Epithelial - + 
MP28 Biphasic + - 
MP29 Epithelial - + 
MP3 Biphasic + - 
MP31 Epithelial - + 
MP32 Epithelial - + 
MP33 Epithelial - + 
MP36 Epithelial - - 
MP37 Epithelial - - 
MP39 Epithelial - - 
MP4 Epithelial + - 
MP41 Biphasic - - 
MP42 Epithelial + - 
MP43 Epithelial + - 
MP46 Epithelial - - 
MP48A Epithelial - - 
MP51 Epithelial + + 
MP52 Epithelial - - 
MP53 Epithelial + - 
MP54 Epithelial - - 
MP55 Epithelial - + 
MP57 Epithelial + - 
MP58 Epithelial - - 
MP59 / - + 
MP60 Epithelial + - 
MP62 Epithelial + + 
MP63 Epithelial - - 
MP64 Epithelial + - 
MP65 Epithelial + - 
MP66 / - - 
MP67 Epithelial + - 
MP68 Epithelial + - 
MP69 Epithelial - - 
MP70A Epithelial - - 
MP71 Epithelial - - 
MP72 Epithelial - - 
MP73 Epithelial + - 
MP74 Epithelial + - 
MP76 Epithelial - + 
MP7A / + - 
MP8A Epithelial + - 
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Supplementary table 2 
miRNA which are differentially expressed in peritoneal mesothelioma among 
TA-positive and TA-negative classes. Number of miRNAs significant at 0.05 
level of the univariate test: 84, sorted by p-value of the univariate test. FDR: 
false discovery rate. 
  
Parametric 
p-value 
FDR 
Geom 
mean of 
intensities 
in class 
TA- 
Geom 
mean of 
intensities 
in class 
TA+ 
Fold-
change 
Gene symbol 
 	
   	 	 hsa-miR-1305
	 
  	 	  hsa-miR-380*
 	  			   HS_177
     	 HS_40
    	 	 hsa-miR-548a-3p
 	     hsa-miR-609
   	 	 	 hsa-miR-1257
      hsa-miR-200b*
    		  hsa-miR-1231
 	  	  	 HS_152
 	   	 	 HS_19
	   		   hsa-miR-122*
    	  hsa-miR-34a*
   		 	  hsa-miR-1262
 	  	   HS_150
 	     HS_268
 	  	 	 	 HS_275
    	  HS_145.1
 		     hsa-miR-1261
	 	     hsa-miR-100
	    	  hsa-miR-519b-3p
		   	 	  hsa-miR-589*
	   	   hsa-miR-548m
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Supplementary table 3 
miRNA which are differentially expressed in peritoneal mesothelioma among 
ALT-positive and ALT-negative classes. Number of miRNAs significant at 0.05 
level of the univariate test: 61, sorted by p-value of the univariate test. FDR: 
false discovery rate.
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Supplementary table 4 
Characteristics of MPNST specimens included for miRNA expression profiling. 
case Syndrome Lesion SITE TA APB
S0290 sporadic P extremities - - 
S0762R sporadic R extremities - + 
S0767M NF1 M extremities + - 
S0779 NF1 P trunk - + 
S0784 NF1 M extremities + + 
S0802R NF1 R extremities + - 
S0900 sporadic R extremities + - 
S1223 sporadic P trunk - + 
S1228 sporadic P trunk - - 
S980R sporadic R extremities - - 
S1313 NF1 P trunk + - 
S0298 sporadic P extremities - + 
S1383 NF1 P trunk - - 
S1743 NF1 R trunk - - 
S1768 sporadic P trunk + - 
S1792 sporadic P extremities + - 
S1209 NF1 P extremities + - 
S1222 sporadic P extremities - - 
S1315 NF1 P extremities - - 
S1488 sporadic P extremities - - 
S1502 sporadic P trunk + - 
S1538 sporadic P extremities - - 
S0306 sporadic P extremities + + 
S0530R NF1 R extremities + + 
S0600M sporadic M extremities + + 
S0656M NF1 R extremities - - 
S0737 sporadic P extremities - + 
S738M sporadic M extremities + - 
S0758 NF1 P trunk + - 
NF1: neurofibromatosis type 1 syndrome; P:primitive lesion, R: recurrent 
lesion, M:metastatic lesion. 
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Supplementary table 5 
miRNA which are differentially expressed in malignant peripheral nerve sheat 
tumors among TA-positive and TA-negative classes. Number of miRNAs 
significant at 0.01 level of the univariate test: 32, sorted by p-value of the 
univariate test. FDR: false discovery rate.
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Supplementary table 6 
miRNA which are differentially expressed in malignant peripheral nerve sheat 
tumors among ALT-positive and ALT-negative classes. Number of miRNAs 
significant at 0.01 level of the univariate test: 15, sorted by p-value of the 
univariate test. FDR: false discovery rate. 
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Supplementary figure 1 
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